{
    "PMC8668943_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "FCGR2C",
                        "gene copy number": "1 copy",
                        "reference group": "2 copies",
                        "analysis type": "univariate",
                        "odds ratio": "0.29",
                        "confidence interval": "0.12-0.71",
                        "P-value": "0.007",
                        "Bonferroni corrected P-value": "0.112"
                    },
                    "measures": "[odds ratio, confidence interval, P-value, Bonferroni corrected P-value]",
                    "outcomes": "[0.29, 0.12-0.71, 0.007, 0.112]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "1 copy",
                        "Bonferroni corrected P-value": "0.112"
                    },
                    "measures": "[Univariate OR, 95% CI, P-value]",
                    "outcomes": "[0.29, (0.12-0.71), 0.007]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "FCGR2C",
                        "gene copy number": "1 copy",
                        "reference group": "2 copies",
                        "analysis type": "adjusted",
                        "adjusted odds ratio": "0.37",
                        "confidence interval": "0.15-0.90",
                        "P-value": "0.029",
                        "Bonferroni corrected P-value": "0.464"
                    },
                    "measures": "[adjusted odds ratio, confidence interval, P-value, Bonferroni corrected P-value]",
                    "outcomes": "[0.37, 0.15-0.90, 0.029, 0.464]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "1 copy",
                        "Bonferroni corrected P-value": "0.464"
                    },
                    "measures": "[Adjusted OR, 95%CI, P-value]",
                    "outcomes": "[0.37 (0.15-0.90), 0.029]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "FCGR2C",
                        "gene copy number": "2 copies",
                        "reference group": "self",
                        "analysis type": "univariate",
                        "odds ratio": "Ref",
                        "P-value": "N/A",
                        "Bonferroni corrected P-value": "N/A"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "2 copies",
                        "statistical measure": "Adjusted OR",
                        "value": "Ref"
                    }
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "FCGR2C",
                        "gene copy number": "2 copies",
                        "reference group": "self",
                        "analysis type": "adjusted",
                        "adjusted odds ratio": "Ref",
                        "P-value": "N/A",
                        "Bonferroni corrected P-value": "N/A"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "\u22653 copies"
                    },
                    "measures": "[Univariate OR, 95% CI, P-value]",
                    "outcomes": "[0.99, (0.63-1.57), 0.978]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "FCGR2C",
                        "gene copy number": "2 copies",
                        "reference group": "self",
                        "analysis type": "adjusted",
                        "adjusted odds ratio": "Ref",
                        "P-value": "N/A",
                        "Bonferroni corrected P-value": "N/A"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "\u22653 copies"
                    },
                    "measures": "[Adjusted OR, 95% CI, P-value]",
                    "outcomes": "[0.74, (0.43-1.27), 0.275]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "FCGR2C",
                        "gene copy number": "\u22653 copies",
                        "reference group": "2 copies",
                        "analysis type": "univariate",
                        "odds ratio": "0.99",
                        "confidence interval": "0.63-1.57",
                        "P-value": "0.978",
                        "Bonferroni corrected P-value": "N/A"
                    },
                    "measures": "[odds ratio, confidence interval, P-value]",
                    "outcomes": "[0.99, 0.63-1.57, 0.978]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "\u22653 copies"
                    },
                    "measures": "[Univariate OR, 95% CI, P-value]",
                    "outcomes": "[0.99, (0.63-1.57), 0.978]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "FCGR2C",
                        "gene copy number": "\u22653 copies",
                        "reference group": "2 copies",
                        "analysis type": "adjusted",
                        "adjusted odds ratio": "0.74",
                        "confidence interval": "0.43-1.27",
                        "P-value": "0.275",
                        "Bonferroni corrected P-value": "N/A"
                    },
                    "measures": "[adjusted odds ratio, confidence interval, P-value]",
                    "outcomes": "[0.74, 0.43-1.27, 0.275]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "\u22653 copies"
                    },
                    "measures": "[Adjusted OR, 95% CI, P-value]",
                    "outcomes": "[0.74, (0.43-1.27), 0.275]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 6,
        "total_ground_truth_claims": 5,
        "number_of_matches": 5
    },
    "PMC5817808_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "ERF",
                        "feeding_option_mortality_rate": "2.41%",
                        "mortality_rate_comparison_to_EBF": "5.5 folds lower",
                        "mortality_rate_comparison_to_MF": "5.5 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.35 [0.52-3.49]",
                        "0.54"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "ERF",
                        "feeding_option_mortality_rate": "2.41%",
                        "mortality_rate_comparison_to_EBF": "5.5 folds lower",
                        "mortality_rate_comparison_to_MF": "5.5 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.16 [0.44-3.08]",
                        "0.76"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "ERF",
                        "feeding_option_mortality_rate": "2.41%",
                        "mortality_rate_comparison_to_EBF": "5.5 folds lower",
                        "mortality_rate_comparison_to_MF": "5.5 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "ERF",
                        "feeding_option_mortality_rate": "2.41%",
                        "mortality_rate_comparison_to_EBF": "5.5 folds lower",
                        "mortality_rate_comparison_to_MF": "5.5 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "ERF",
                        "feeding_option_mortality_rate": "2.41%",
                        "mortality_rate_comparison_to_EBF": "5.5 folds lower",
                        "mortality_rate_comparison_to_MF": "5.5 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Mixed feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.31 [0.04-2.42]",
                        "0.26"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "ERF",
                        "feeding_option_mortality_rate": "2.41%",
                        "mortality_rate_comparison_to_EBF": "5.5 folds lower",
                        "mortality_rate_comparison_to_MF": "5.5 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Mixed feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.44 [0.053-3.74]",
                        "0.45"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "ERF",
                        "feeding_option_mortality_rate": "2.41%",
                        "mortality_rate_comparison_to_EBF": "5.5 folds lower",
                        "mortality_rate_comparison_to_MF": "5.5 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Positive"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.31 [0.11-0.90]",
                        "0.032"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "ERF",
                        "feeding_option_mortality_rate": "2.41%",
                        "mortality_rate_comparison_to_EBF": "5.5 folds lower",
                        "mortality_rate_comparison_to_MF": "5.5 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Positive"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.30 [0.08-1.11]",
                        "0.071"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "ERF",
                        "feeding_option_mortality_rate": "2.41%",
                        "mortality_rate_comparison_to_EBF": "5.5 folds lower",
                        "mortality_rate_comparison_to_MF": "5.5 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Negative"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "ERF",
                        "feeding_option_mortality_rate": "2.41%",
                        "mortality_rate_comparison_to_EBF": "5.5 folds lower",
                        "mortality_rate_comparison_to_MF": "5.5 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Negative"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "ERF",
                        "feeding_option_mortality_rate": "2.41%",
                        "mortality_rate_comparison_to_EBF": "5.5 folds lower",
                        "mortality_rate_comparison_to_MF": "5.5 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": ">= 2500 g"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.70 [0.16-2.96]",
                        "0.63"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "ERF",
                        "feeding_option_mortality_rate": "2.41%",
                        "mortality_rate_comparison_to_EBF": "5.5 folds lower",
                        "mortality_rate_comparison_to_MF": "5.5 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": ">= 2500 g"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.93 [0.21-4.12]",
                        "0.92"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "ERF",
                        "feeding_option_mortality_rate": "2.41%",
                        "mortality_rate_comparison_to_EBF": "5.5 folds lower",
                        "mortality_rate_comparison_to_MF": "5.5 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": "< 2500 g"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "ERF",
                        "feeding_option_mortality_rate": "2.41%",
                        "mortality_rate_comparison_to_EBF": "5.5 folds lower",
                        "mortality_rate_comparison_to_MF": "5.5 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": "< 2500 g"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "ERF",
                        "feeding_option_mortality_rate": "2.41%",
                        "mortality_rate_comparison_to_EBF": "5.5 folds lower",
                        "mortality_rate_comparison_to_MF": "5.5 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Global Schoenfeld residuals test",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program"
                    },
                    "measures": [
                        "p-value"
                    ],
                    "outcomes": [
                        "0.23"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "EBF",
                        "feeding_option_mortality_rate": "2.45%",
                        "mortality_rate_comparison_to_ERF": "5.4 folds lower",
                        "mortality_rate_comparison_to_MF": "5.4 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.35 [0.52-3.49]",
                        "0.54"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "EBF",
                        "feeding_option_mortality_rate": "2.45%",
                        "mortality_rate_comparison_to_ERF": "5.4 folds lower",
                        "mortality_rate_comparison_to_MF": "5.4 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.16 [0.44-3.08]",
                        "0.76"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "EBF",
                        "feeding_option_mortality_rate": "2.45%",
                        "mortality_rate_comparison_to_ERF": "5.4 folds lower",
                        "mortality_rate_comparison_to_MF": "5.4 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "EBF",
                        "feeding_option_mortality_rate": "2.45%",
                        "mortality_rate_comparison_to_ERF": "5.4 folds lower",
                        "mortality_rate_comparison_to_MF": "5.4 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "EBF",
                        "feeding_option_mortality_rate": "2.45%",
                        "mortality_rate_comparison_to_ERF": "5.4 folds lower",
                        "mortality_rate_comparison_to_MF": "5.4 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Mixed feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.31 [0.04-2.42]",
                        "0.26"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "EBF",
                        "feeding_option_mortality_rate": "2.45%",
                        "mortality_rate_comparison_to_ERF": "5.4 folds lower",
                        "mortality_rate_comparison_to_MF": "5.4 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Mixed feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.44 [0.053-3.74]",
                        "0.45"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "EBF",
                        "feeding_option_mortality_rate": "2.45%",
                        "mortality_rate_comparison_to_ERF": "5.4 folds lower",
                        "mortality_rate_comparison_to_MF": "5.4 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Positive"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.31 [0.11-0.90]",
                        "0.032"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "EBF",
                        "feeding_option_mortality_rate": "2.45%",
                        "mortality_rate_comparison_to_ERF": "5.4 folds lower",
                        "mortality_rate_comparison_to_MF": "5.4 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Positive"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.30 [0.08-1.11]",
                        "0.071"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "EBF",
                        "feeding_option_mortality_rate": "2.45%",
                        "mortality_rate_comparison_to_ERF": "5.4 folds lower",
                        "mortality_rate_comparison_to_MF": "5.4 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Negative"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "EBF",
                        "feeding_option_mortality_rate": "2.45%",
                        "mortality_rate_comparison_to_ERF": "5.4 folds lower",
                        "mortality_rate_comparison_to_MF": "5.4 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Negative"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "EBF",
                        "feeding_option_mortality_rate": "2.45%",
                        "mortality_rate_comparison_to_ERF": "5.4 folds lower",
                        "mortality_rate_comparison_to_MF": "5.4 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": ">= 2500 g"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.70 [0.16-2.96]",
                        "0.63"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "EBF",
                        "feeding_option_mortality_rate": "2.45%",
                        "mortality_rate_comparison_to_ERF": "5.4 folds lower",
                        "mortality_rate_comparison_to_MF": "5.4 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": ">= 2500 g"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.93 [0.21-4.12]",
                        "0.92"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "EBF",
                        "feeding_option_mortality_rate": "2.45%",
                        "mortality_rate_comparison_to_ERF": "5.4 folds lower",
                        "mortality_rate_comparison_to_MF": "5.4 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": "< 2500 g"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "EBF",
                        "feeding_option_mortality_rate": "2.45%",
                        "mortality_rate_comparison_to_ERF": "5.4 folds lower",
                        "mortality_rate_comparison_to_MF": "5.4 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": "< 2500 g"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "EBF",
                        "feeding_option_mortality_rate": "2.45%",
                        "mortality_rate_comparison_to_ERF": "5.4 folds lower",
                        "mortality_rate_comparison_to_MF": "5.4 folds lower"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Global Schoenfeld residuals test",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program"
                    },
                    "measures": [
                        "p-value"
                    ],
                    "outcomes": [
                        "0.23"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "MF",
                        "feeding_option_mortality_rate": "13.33%",
                        "mortality_rate_comparison_to_EBF": "5.4 folds higher",
                        "mortality_rate_comparison_to_ERF": "5.5 folds higher"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.35 [0.52-3.49]",
                        "0.54"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "MF",
                        "feeding_option_mortality_rate": "13.33%",
                        "mortality_rate_comparison_to_EBF": "5.4 folds higher",
                        "mortality_rate_comparison_to_ERF": "5.5 folds higher"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.16 [0.44-3.08]",
                        "0.76"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "MF",
                        "feeding_option_mortality_rate": "13.33%",
                        "mortality_rate_comparison_to_EBF": "5.4 folds higher",
                        "mortality_rate_comparison_to_ERF": "5.5 folds higher"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "MF",
                        "feeding_option_mortality_rate": "13.33%",
                        "mortality_rate_comparison_to_EBF": "5.4 folds higher",
                        "mortality_rate_comparison_to_ERF": "5.5 folds higher"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "MF",
                        "feeding_option_mortality_rate": "13.33%",
                        "mortality_rate_comparison_to_EBF": "5.4 folds higher",
                        "mortality_rate_comparison_to_ERF": "5.5 folds higher"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Mixed feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.31 [0.04-2.42]",
                        "0.26"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "MF",
                        "feeding_option_mortality_rate": "13.33%",
                        "mortality_rate_comparison_to_EBF": "5.4 folds higher",
                        "mortality_rate_comparison_to_ERF": "5.5 folds higher"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Mixed feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.44 [0.053-3.74]",
                        "0.45"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "MF",
                        "feeding_option_mortality_rate": "13.33%",
                        "mortality_rate_comparison_to_EBF": "5.4 folds higher",
                        "mortality_rate_comparison_to_ERF": "5.5 folds higher"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Positive"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.31 [0.11-0.90]",
                        "0.032"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "MF",
                        "feeding_option_mortality_rate": "13.33%",
                        "mortality_rate_comparison_to_EBF": "5.4 folds higher",
                        "mortality_rate_comparison_to_ERF": "5.5 folds higher"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Positive"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.30 [0.08-1.11]",
                        "0.071"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "MF",
                        "feeding_option_mortality_rate": "13.33%",
                        "mortality_rate_comparison_to_EBF": "5.4 folds higher",
                        "mortality_rate_comparison_to_ERF": "5.5 folds higher"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Negative"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "MF",
                        "feeding_option_mortality_rate": "13.33%",
                        "mortality_rate_comparison_to_EBF": "5.4 folds higher",
                        "mortality_rate_comparison_to_ERF": "5.5 folds higher"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Negative"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "MF",
                        "feeding_option_mortality_rate": "13.33%",
                        "mortality_rate_comparison_to_EBF": "5.4 folds higher",
                        "mortality_rate_comparison_to_ERF": "5.5 folds higher"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": ">= 2500 g"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.70 [0.16-2.96]",
                        "0.63"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "MF",
                        "feeding_option_mortality_rate": "13.33%",
                        "mortality_rate_comparison_to_EBF": "5.4 folds higher",
                        "mortality_rate_comparison_to_ERF": "5.5 folds higher"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": ">= 2500 g"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.93 [0.21-4.12]",
                        "0.92"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "MF",
                        "feeding_option_mortality_rate": "13.33%",
                        "mortality_rate_comparison_to_EBF": "5.4 folds higher",
                        "mortality_rate_comparison_to_ERF": "5.5 folds higher"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": "< 2500 g"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "MF",
                        "feeding_option_mortality_rate": "13.33%",
                        "mortality_rate_comparison_to_EBF": "5.4 folds higher",
                        "mortality_rate_comparison_to_ERF": "5.5 folds higher"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": "< 2500 g"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population_mortality_rate": "2.58%",
                        "feeding_option": "MF",
                        "feeding_option_mortality_rate": "13.33%",
                        "mortality_rate_comparison_to_EBF": "5.4 folds higher",
                        "mortality_rate_comparison_to_ERF": "5.5 folds higher"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Global Schoenfeld residuals test",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program"
                    },
                    "measures": [
                        "p-value"
                    ],
                    "outcomes": [
                        "0.23"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "feeding_option": "Exclusive breast feeding",
                        "unadjusted_HR": "1.35 [0.52-3.49]",
                        "adjusted_HR": "1.16 [0.44-3.08]"
                    },
                    "measures": "[0.52-3.49]",
                    "outcomes": [
                        "[0.44-3.08]",
                        "[p_unadjusted, p_adjusted]",
                        "[0.54, 0.76]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.35 [0.52-3.49]",
                        "0.54"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "feeding_option": "Mixed feeding",
                        "unadjusted_HR": "0.31 [0.04-2.42]",
                        "adjusted_HR": "0.44 [0.053-3.74]"
                    },
                    "measures": "[0.04-2.42]",
                    "outcomes": [
                        "[0.053-3.74]",
                        "[p_unadjusted, p_adjusted]",
                        "[0.26, 0.45]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.16 [0.44-3.08]",
                        "0.76"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "feeding_option": "Mixed feeding",
                        "unadjusted_HR": "0.31 [0.04-2.42]",
                        "adjusted_HR": "0.44 [0.053-3.74]"
                    },
                    "measures": "[0.04-2.42]",
                    "outcomes": [
                        "[0.053-3.74]",
                        "[p_unadjusted, p_adjusted]",
                        "[0.26, 0.45]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "feeding_option": "Mixed feeding",
                        "unadjusted_HR": "0.31 [0.04-2.42]",
                        "adjusted_HR": "0.44 [0.053-3.74]"
                    },
                    "measures": "[0.04-2.42]",
                    "outcomes": [
                        "[0.053-3.74]",
                        "[p_unadjusted, p_adjusted]",
                        "[0.26, 0.45]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "feeding_option": "Mixed feeding",
                        "unadjusted_HR": "0.31 [0.04-2.42]",
                        "adjusted_HR": "0.44 [0.053-3.74]"
                    },
                    "measures": "[0.04-2.42]",
                    "outcomes": [
                        "[0.053-3.74]",
                        "[p_unadjusted, p_adjusted]",
                        "[0.26, 0.45]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Mixed feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.31 [0.04-2.42]",
                        "0.26"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "feeding_option": "Exclusive replacement feeding",
                        "unadjusted_HR": "Ref",
                        "adjusted_HR": "Ref"
                    },
                    "measures": "[p_unadjusted, p_adjusted]",
                    "outcomes": "[Ref, Ref]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.16 [0.44-3.08]",
                        "0.76"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "feeding_option": "Exclusive replacement feeding",
                        "unadjusted_HR": "Ref",
                        "adjusted_HR": "Ref"
                    },
                    "measures": "[p_unadjusted, p_adjusted]",
                    "outcomes": "[Ref, Ref]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "HIV_status": "Positive",
                        "unadjusted_HR": "0.31 [0.11-0.90]",
                        "adjusted_HR": "0.30 [0.08-1.11]"
                    },
                    "measures": "[0.11-0.90]",
                    "outcomes": [
                        "[0.08-1.11]",
                        "[p_unadjusted, p_adjusted]",
                        "[0.032, 0.071]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.16 [0.44-3.08]",
                        "0.76"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "HIV_status": "Positive",
                        "unadjusted_HR": "0.31 [0.11-0.90]",
                        "adjusted_HR": "0.30 [0.08-1.11]"
                    },
                    "measures": "[0.11-0.90]",
                    "outcomes": [
                        "[0.08-1.11]",
                        "[p_unadjusted, p_adjusted]",
                        "[0.032, 0.071]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "HIV_status": "Positive",
                        "unadjusted_HR": "0.31 [0.11-0.90]",
                        "adjusted_HR": "0.30 [0.08-1.11]"
                    },
                    "measures": "[0.11-0.90]",
                    "outcomes": [
                        "[0.08-1.11]",
                        "[p_unadjusted, p_adjusted]",
                        "[0.032, 0.071]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Mixed feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.44 [0.053-3.74]",
                        "0.45"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "HIV_status": "Positive",
                        "unadjusted_HR": "0.31 [0.11-0.90]",
                        "adjusted_HR": "0.30 [0.08-1.11]"
                    },
                    "measures": "[0.11-0.90]",
                    "outcomes": [
                        "[0.08-1.11]",
                        "[p_unadjusted, p_adjusted]",
                        "[0.032, 0.071]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Positive"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.31 [0.11-0.90]",
                        "0.032"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "HIV_status": "Positive",
                        "unadjusted_HR": "0.31 [0.11-0.90]",
                        "adjusted_HR": "0.30 [0.08-1.11]"
                    },
                    "measures": "[0.11-0.90]",
                    "outcomes": [
                        "[0.08-1.11]",
                        "[p_unadjusted, p_adjusted]",
                        "[0.032, 0.071]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Positive"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.30 [0.08-1.11]",
                        "0.071"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "HIV_status": "Negative",
                        "unadjusted_HR": "Ref",
                        "adjusted_HR": "Ref"
                    },
                    "measures": "[p_unadjusted, p_adjusted]",
                    "outcomes": "[Ref, Ref]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.16 [0.44-3.08]",
                        "0.76"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "HIV_status": "Negative",
                        "unadjusted_HR": "Ref",
                        "adjusted_HR": "Ref"
                    },
                    "measures": "[p_unadjusted, p_adjusted]",
                    "outcomes": "[Ref, Ref]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "HIV_status": "Negative",
                        "unadjusted_HR": "Ref",
                        "adjusted_HR": "Ref"
                    },
                    "measures": "[p_unadjusted, p_adjusted]",
                    "outcomes": "[Ref, Ref]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Mixed feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.44 [0.053-3.74]",
                        "0.45"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "HIV_status": "Negative",
                        "unadjusted_HR": "Ref",
                        "adjusted_HR": "Ref"
                    },
                    "measures": "[p_unadjusted, p_adjusted]",
                    "outcomes": "[Ref, Ref]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Positive"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.31 [0.11-0.90]",
                        "0.032"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "HIV_status": "Negative",
                        "unadjusted_HR": "Ref",
                        "adjusted_HR": "Ref"
                    },
                    "measures": "[p_unadjusted, p_adjusted]",
                    "outcomes": "[Ref, Ref]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Negative"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "birth_weight": ">=2500 g",
                        "unadjusted_HR": "0.88 [0.34-2.28]",
                        "adjusted_HR": "0.93 [0.21-4.12]"
                    },
                    "measures": "[0.34-2.28]",
                    "outcomes": [
                        "[0.21-4.12]",
                        "[p_unadjusted, p_adjusted]",
                        "[0.80, 0.92]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.16 [0.44-3.08]",
                        "0.76"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "birth_weight": ">=2500 g",
                        "unadjusted_HR": "0.88 [0.34-2.28]",
                        "adjusted_HR": "0.93 [0.21-4.12]"
                    },
                    "measures": "[0.34-2.28]",
                    "outcomes": [
                        "[0.21-4.12]",
                        "[p_unadjusted, p_adjusted]",
                        "[0.80, 0.92]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "birth_weight": ">=2500 g",
                        "unadjusted_HR": "0.88 [0.34-2.28]",
                        "adjusted_HR": "0.93 [0.21-4.12]"
                    },
                    "measures": "[0.34-2.28]",
                    "outcomes": [
                        "[0.21-4.12]",
                        "[p_unadjusted, p_adjusted]",
                        "[0.80, 0.92]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Mixed feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.44 [0.053-3.74]",
                        "0.45"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "birth_weight": ">=2500 g",
                        "unadjusted_HR": "0.88 [0.34-2.28]",
                        "adjusted_HR": "0.93 [0.21-4.12]"
                    },
                    "measures": "[0.34-2.28]",
                    "outcomes": [
                        "[0.21-4.12]",
                        "[p_unadjusted, p_adjusted]",
                        "[0.80, 0.92]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Positive"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.31 [0.11-0.90]",
                        "0.032"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "birth_weight": ">=2500 g",
                        "unadjusted_HR": "0.88 [0.34-2.28]",
                        "adjusted_HR": "0.93 [0.21-4.12]"
                    },
                    "measures": "[0.34-2.28]",
                    "outcomes": [
                        "[0.21-4.12]",
                        "[p_unadjusted, p_adjusted]",
                        "[0.80, 0.92]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Negative"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "birth_weight": ">=2500 g",
                        "unadjusted_HR": "0.88 [0.34-2.28]",
                        "adjusted_HR": "0.93 [0.21-4.12]"
                    },
                    "measures": "[0.34-2.28]",
                    "outcomes": [
                        "[0.21-4.12]",
                        "[p_unadjusted, p_adjusted]",
                        "[0.80, 0.92]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": ">= 2500 g"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.70 [0.16-2.96]",
                        "0.63"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "birth_weight": ">=2500 g",
                        "unadjusted_HR": "0.88 [0.34-2.28]",
                        "adjusted_HR": "0.93 [0.21-4.12]"
                    },
                    "measures": "[0.34-2.28]",
                    "outcomes": [
                        "[0.21-4.12]",
                        "[p_unadjusted, p_adjusted]",
                        "[0.80, 0.92]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": ">= 2500 g"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.93 [0.21-4.12]",
                        "0.92"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "birth_weight": "<2500 g",
                        "unadjusted_HR": "Ref",
                        "adjusted_HR": "Ref"
                    },
                    "measures": "[p_unadjusted, p_adjusted]",
                    "outcomes": "[Ref, Ref]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.16 [0.44-3.08]",
                        "0.76"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "birth_weight": "<2500 g",
                        "unadjusted_HR": "Ref",
                        "adjusted_HR": "Ref"
                    },
                    "measures": "[p_unadjusted, p_adjusted]",
                    "outcomes": "[Ref, Ref]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "test": "Global Schoenfeld residuals test"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.16 [0.44-3.08]",
                        "0.76"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "test": "Global Schoenfeld residuals test"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Mixed feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.44 [0.053-3.74]",
                        "0.45"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "test": "Global Schoenfeld residuals test"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Positive"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.31 [0.11-0.90]",
                        "0.032"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "test": "Global Schoenfeld residuals test"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Negative"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "test": "Global Schoenfeld residuals test"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": ">= 2500 g"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.70 [0.16-2.96]",
                        "0.63"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "test": "Global Schoenfeld residuals test"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": "< 2500 g"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "test": "Global Schoenfeld residuals test"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": "< 2500 g"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "HIV exposed infants",
                        "study_location": "Essos hospital center",
                        "program": "PMTCT",
                        "age": "24 months",
                        "test": "Global Schoenfeld residuals test"
                    },
                    "measures": "[p]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Global Schoenfeld residuals test",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program"
                    },
                    "measures": [
                        "p-value"
                    ],
                    "outcomes": [
                        "0.23"
                    ]
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 11,
        "total_ground_truth_claims": 15,
        "number_of_matches": 8
    },
    "PMC5574138_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "covariate": "Length of follow-up",
                        "estimate": "-0.0138",
                        "standard error": "0.0666",
                        "confidence interval": "(-0.1322\u20130.1046)",
                        "analysis type": "meta-regression",
                        "dependent variable": "study",
                        "independent variables": "covariates",
                        "context": "regression model",
                        "additional covariates": "length of follow-up, median CD4 cell counts, median age, year of publication, proportion of female"
                    },
                    "measures": "[estimate, standard error, confidence interval]",
                    "outcomes": "[-0.0138, 0.0666, (-0.1322\u20130.1046)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Covariate": "Length of follow-up",
                        "Method": "Meta-regression"
                    },
                    "measures": "[Estimate, S.E, 95% CI]",
                    "outcomes": "[-0.0138, 0.0666, (-0.1322\u20130.1046)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "covariate": "Median CD4 count",
                        "estimate": "-0.0034",
                        "standard error": "0.0066",
                        "confidence interval": "(-0.0150\u20130.0079)",
                        "analysis type": "meta-regression",
                        "dependent variable": "study",
                        "independent variables": "covariates",
                        "context": "regression model",
                        "additional covariates": "length of follow-up, median CD4 cell counts, median age, year of publication, proportion of female"
                    },
                    "measures": "[estimate, standard error, confidence interval]",
                    "outcomes": "[-0.0034, 0.0066, (-0.0150\u20130.0079)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Covariate": "Median CD4 count",
                        "Method": "Meta-regression"
                    },
                    "measures": "[Estimate, S.E, 95% CI]",
                    "outcomes": "[-0.0034, 0.0066, (-0.0150\u20130.0079)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "covariate": "Median age",
                        "estimate": "0.0415",
                        "standard error": "0.0503",
                        "confidence interval": "(-0.1013\u20130.0755)",
                        "analysis type": "meta-regression",
                        "dependent variable": "study",
                        "independent variables": "covariates",
                        "context": "regression model",
                        "additional covariates": "length of follow-up, median CD4 cell counts, median age, year of publication, proportion of female"
                    },
                    "measures": "[estimate, standard error, confidence interval]",
                    "outcomes": "[0.0415, 0.0503, (-0.1013\u20130.0755)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Covariate": "Median age",
                        "Method": "Meta-regression"
                    },
                    "measures": "[Estimate, S.E, 95% CI]",
                    "outcomes": "[0.0415, 0.0503, (-0.1013\u20130.0755)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "covariate": "Year of publication",
                        "estimate": "0.0637",
                        "standard error": "0.0815",
                        "confidence interval": "(-0.1736\u20130.0980)",
                        "analysis type": "meta-regression",
                        "dependent variable": "study",
                        "independent variables": "covariates",
                        "context": "regression model",
                        "additional covariates": "length of follow-up, median CD4 cell counts, median age, year of publication, proportion of female"
                    },
                    "measures": "[estimate, standard error, confidence interval]",
                    "outcomes": "[0.0637, 0.0815, (-0.1736\u20130.0980)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Covariate": "Year of publication",
                        "Method": "Meta-regression"
                    },
                    "measures": "[Estimate, S.E, 95% CI]",
                    "outcomes": "[0.0637, 0.0815, (-0.1736\u20130.0980)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "covariate": "Female proportion",
                        "estimate": "-0.5305",
                        "standard error": "1.4575",
                        "confidence interval": "(-3.6792\u20132.6183)",
                        "analysis type": "meta-regression",
                        "dependent variable": "study",
                        "independent variables": "covariates",
                        "context": "regression model",
                        "additional covariates": "length of follow-up, median CD4 cell counts, median age, year of publication, proportion of female"
                    },
                    "measures": "[estimate, standard error, confidence interval]",
                    "outcomes": "[-0.5305, 1.4575, (-3.6792\u20132.6183)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Covariate": "Female proportion",
                        "Method": "Meta-regression"
                    },
                    "measures": "[Estimate, S.E, 95% CI]",
                    "outcomes": "[-0.5305, 1.4575, (-3.6792\u20132.6183)]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 5,
        "total_ground_truth_claims": 5,
        "number_of_matches": 5
    },
    "PMC4794224_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR Genotypes": "KIR2DL1",
                        "Frequency": "97%",
                        "N": "966"
                    },
                    "measures": "[Frequency]",
                    "outcomes": "[97%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "97%",
                        "966"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR Genotypes": "KIR2DL3",
                        "Frequency": "72%",
                        "N": "719"
                    },
                    "measures": "[Frequency]",
                    "outcomes": "[72%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL3"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "72%",
                        "719"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR Genotypes": "KIR2DL4",
                        "Frequency": "100%",
                        "N": "993"
                    },
                    "measures": "[Frequency]",
                    "outcomes": "[100%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL4"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "100%",
                        "993"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR Genotypes": "KIR2DL5",
                        "Frequency": "55%",
                        "N": "547"
                    },
                    "measures": "[Frequency]",
                    "outcomes": "[55%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL5"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "55%",
                        "547"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR Genotypes": "KIR2DL2*004",
                        "Frequency": "3%",
                        "N": "31"
                    },
                    "measures": "[Frequency]",
                    "outcomes": "[3%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL2*004"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "3%",
                        "31"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR Genotypes": "KIR2DL2*001/2/3/5",
                        "Frequency": "55%",
                        "N": "544"
                    },
                    "measures": "[Frequency]",
                    "outcomes": "[55%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL2*001/2/3/5"
                    },
                    "measures": [
                        "Positive Frequency, N"
                    ],
                    "outcomes": [
                        "55%",
                        "544"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR Genotypes": "KIR2DP1",
                        "Frequency": "97%",
                        "N": "964"
                    },
                    "measures": "[Frequency]",
                    "outcomes": "[97%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DP1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "97%",
                        "964"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR Genotypes": "KIR2DS1",
                        "Frequency": "55%",
                        "N": "548"
                    },
                    "measures": "[Frequency]",
                    "outcomes": "[55%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "55%",
                        "548"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR Genotypes": "KIR2DS2",
                        "Frequency": "59%",
                        "N": "581"
                    },
                    "measures": "[Frequency]",
                    "outcomes": "[59%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS2"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "59%",
                        "581"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR Genotypes": "KIR2DS3",
                        "Frequency": "40%",
                        "N": "401"
                    },
                    "measures": "[Frequency]",
                    "outcomes": "[40%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS3"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "40%",
                        "401"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR Genotypes": "KIR2DS4",
                        "Frequency": "100%",
                        "N": "993"
                    },
                    "measures": "[Frequency]",
                    "outcomes": "[100%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS4"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "100%",
                        "993"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR Genotypes": "KIR2DS5",
                        "Frequency": "28%",
                        "N": "281"
                    },
                    "measures": "[Frequency]",
                    "outcomes": "[28%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS5"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "28%",
                        "281"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR Genotypes": "KIR3DL1",
                        "Frequency": "94%",
                        "N": "929"
                    },
                    "measures": "[Frequency]",
                    "outcomes": "[94%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR3DL1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "94%",
                        "929"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR Genotypes": "KIR3DL2",
                        "Frequency": "100%",
                        "N": "993"
                    },
                    "measures": "[Frequency]",
                    "outcomes": "[100%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR3DL2"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "100%",
                        "993"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR Genotypes": "KIR3DL3",
                        "Frequency": "100%",
                        "N": "993"
                    },
                    "measures": "[Frequency]",
                    "outcomes": "[100%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR3DL3"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "100%",
                        "993"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR Genotypes": "KIR3DS1",
                        "Frequency": "36%",
                        "N": "354"
                    },
                    "measures": "[Frequency]",
                    "outcomes": "[36%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR3DS1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "36%",
                        "354"
                    ]
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 18,
        "total_ground_truth_claims": 16,
        "number_of_matches": 16
    },
    "PMC9077443_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "caption": "Cabotegravir effectiveness, overall and by subgroup",
                        "analysis": "ITT",
                        "endpoint": "primary",
                        "group": "TDF-FTC",
                        "events per total PY in cabotegravir group": "4/1956 (0.20%)",
                        "events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                        "HR (95% CI)": "0.12 (0.05\u20130.31)",
                        "p value": "<0.0001"
                    },
                    "measures": "[HR]",
                    "outcomes": "[0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Overall",
                        "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                        "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                        "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.12, 0.05-0.31, <0.0001]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "caption": "Cabotegravir effectiveness, overall and by subgroup",
                        "analysis": "ITT",
                        "endpoint": "primary",
                        "group": "TDF-FTC",
                        "age group": "<25 years",
                        "events per total PY in cabotegravir group": "3/866 (0.35%)",
                        "events per total PY in TDF-FTC group": "20/851 (2.34%)",
                        "HR (95% CI)": "0.17 (0.05\u20130.54)"
                    },
                    "measures": "[HR]",
                    "outcomes": "[0.17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age <25 years",
                        "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                        "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.17, 0.05-0.54, 0.53]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "caption": "Cabotegravir effectiveness, overall and by subgroup",
                        "analysis": "ITT",
                        "endpoint": "primary",
                        "group": "TDF-FTC",
                        "age group": "\u226525 years",
                        "events per total PY in cabotegravir group": "1/1090 (0.09%)",
                        "events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                        "HR (95% CI)": "0.09 (0.02\u20130.49)"
                    },
                    "measures": "[HR]",
                    "outcomes": "[0.09]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age \u226525 years",
                        "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                        "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.09, 0.02-0.49]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "caption": "Cabotegravir effectiveness, overall and by subgroup",
                        "analysis": "ITT",
                        "endpoint": "primary",
                        "group": "TDF-FTC",
                        "contraceptive method": "DMPA",
                        "events per total PY in cabotegravir group": "3/1009 (0.30%)",
                        "events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                        "HR (95% CI)": "0.16 (0.05\u20130.53)"
                    },
                    "measures": "[HR]",
                    "outcomes": "[0.16]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "DMPA contraceptive method",
                        "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                        "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.05-0.53]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "caption": "Cabotegravir effectiveness, overall and by subgroup",
                        "analysis": "ITT",
                        "endpoint": "primary",
                        "group": "TDF-FTC",
                        "contraceptive method": "NET-EN",
                        "events per total PY in cabotegravir group": "1/175 (0.57%)",
                        "events per total PY in TDF-FTC group": "6/182 (3.30%)",
                        "HR (95% CI)": "0.22 (0.03\u20131.48)"
                    },
                    "measures": "[HR]",
                    "outcomes": "[0.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "NET-EN contraceptive method",
                        "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                        "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.22, 0.03-1.48]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "caption": "Cabotegravir effectiveness, overall and by subgroup",
                        "analysis": "ITT",
                        "endpoint": "primary",
                        "group": "TDF-FTC",
                        "contraceptive method": "Implant",
                        "events per total PY in cabotegravir group": "0",
                        "events per total PY in TDF-FTC group": "8/607 (1.32%)",
                        "HR (95% CI)": "0.06 (0.00\u20131.16)"
                    },
                    "measures": "[HR]",
                    "outcomes": "[0.06]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Implant contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.06, 0.00-1.16]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "caption": "Cabotegravir effectiveness, overall and by subgroup",
                        "analysis": "ITT",
                        "endpoint": "primary",
                        "group": "TDF-FTC",
                        "contraceptive method": "Other",
                        "events per total PY in cabotegravir group": "0",
                        "events per total PY in TDF-FTC group": "1/152 (0.66%)",
                        "HR (95% CI)": "0.32 (0.01\u20139.89)"
                    },
                    "measures": "[HR]",
                    "outcomes": "[0.32]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Other contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.32, 0.01-9.89]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "caption": "Cabotegravir effectiveness, overall and by subgroup",
                        "analysis": "ITT",
                        "endpoint": "primary",
                        "group": "TDF-FTC",
                        "BMI group": "\u226430 kg/m\u00b2",
                        "events per total PY in cabotegravir group": "4/1389 (0.29%)",
                        "events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                        "HR (95% CI)": "0.16 (0.06\u20130.45)",
                        "p value": "0.47"
                    },
                    "measures": "[HR]",
                    "outcomes": "[0.16]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI \u226430 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                        "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.06-0.45]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "caption": "Cabotegravir effectiveness, overall and by subgroup",
                        "analysis": "ITT",
                        "endpoint": "primary",
                        "group": "TDF-FTC",
                        "BMI group": ">30 kg/m\u00b2",
                        "events per total PY in cabotegravir group": "0",
                        "events per total PY in TDF-FTC group": "9/495 (1.82%)",
                        "HR (95% CI)": "0.05 (0.00\u20130.96)"
                    },
                    "measures": "[HR]",
                    "outcomes": "[0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI >30 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.05, 0.00-0.96]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 10,
        "total_ground_truth_claims": 9,
        "number_of_matches": 9
    },
    "PMC10294491_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "trial": "DISCOVER",
                        "analysis type": "original analysis on rate ratio scale",
                        "group": "TDF/FTC",
                        "no. subjects": "2693",
                        "PYFU": "4386",
                        "incident HIV infections": "11",
                        "incidence rate (per 100 PYFU)": "0.251",
                        "rate ratio (95% CI)": "REF"
                    },
                    "measures": "[PYFU, incident HIV infections, incidence rate (per 100 PYFU)]",
                    "outcomes": "[4386, 11, 0.251]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Original analysis on rate ratio scale",
                        "Group": "TDF/FTC",
                        "No. subjects": "2693",
                        "PYFU": "4386",
                        "Incident HIV infections": "11",
                        "Method": "Rate ratio analysis"
                    },
                    "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                    "outcomes": "[0.251, REF]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "trial": "DISCOVER",
                        "analysis type": "original analysis on rate ratio scale",
                        "group": "TAF/FTC",
                        "no. subjects": "2694",
                        "PYFU": "4370",
                        "incident HIV infections": "6",
                        "incidence rate (per 100 PYFU)": "0.137",
                        "rate ratio (95% CI)": "0.55 (0.20, 1.48)"
                    },
                    "measures": "[PYFU, incident HIV infections, incidence rate (per 100 PYFU)]",
                    "outcomes": "[4370, 6, 0.137]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Original analysis on rate ratio scale",
                        "Group": "TAF/FTC",
                        "No. subjects": "2694",
                        "PYFU": "4370",
                        "Incident HIV infections": "6",
                        "Method": "Rate ratio analysis"
                    },
                    "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                    "outcomes": "[0.137, 0.55 (0.20\u20131.48)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "trial": "DISCOVER",
                        "analysis type": "re-analysis using an averted infections framework",
                        "group": "TDF/FTC",
                        "PYFU": "4386",
                        "observed infections": "11",
                        "predicted infections": "90.4",
                        "averted infections": "79.4",
                        "averted infections ratio (95% CI)": "REF"
                    },
                    "measures": "[PYFU, observed infections, predicted infections, averted infections]",
                    "outcomes": "[4386, 11, 90.4, 79.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Re-analysis using an averted infections framework",
                        "Group": "TDF/FTC",
                        "PYFU": "4386",
                        "Observed infections": "11",
                        "Predicted infections": "90.4",
                        "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                    },
                    "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                    "outcomes": "[79.4, REF]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "trial": "DISCOVER",
                        "analysis type": "re-analysis using an averted infections framework",
                        "group": "TAF/FTC",
                        "PYFU": "4370",
                        "observed infections": "6",
                        "predicted infections": "90.0",
                        "averted infections": "84.0",
                        "averted infections ratio (95% CI)": "1.06 (0.96\u20131.17)"
                    },
                    "measures": "[PYFU, observed infections, predicted infections, averted infections]",
                    "outcomes": "[4370, 6, 90.0, 84.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Re-analysis using an averted infections framework",
                        "Group": "TAF/FTC",
                        "PYFU": "4370",
                        "Observed infections": "6",
                        "Predicted infections": "90.0",
                        "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                    },
                    "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                    "outcomes": "[84.0, 1.06 (0.96-1.17)]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 6,
        "total_ground_truth_claims": 4,
        "number_of_matches": 4
    },
    "PMC6158807_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "event_type": "Composite endpoint",
                        "total_events": "692",
                        "no_of_event": "123",
                        "person_year_follow_up": "4071",
                        "rate_per_100_person_year": "3.02",
                        "rate_95_CI": "(2.53\u20133.61)"
                    },
                    "measures": "[no_of_event, person_year_follow_up, rate_per_100_person_year]",
                    "outcomes": "[123, 4071, 3.02]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Composite endpoint (all participants)",
                        "Sample size": "692",
                        "No. of events": "123",
                        "Person-years of follow-up": "4071",
                        "Method": "Event rate across total follow-up"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[3.02 (2.53\u20133.61)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "event_type": "Composite endpoint",
                        "total_events": "692",
                        "current_CD4_CD8_ratio": "< 0.3",
                        "no_of_event": "21",
                        "person_year_follow_up": "184",
                        "rate_per_100_person_year": "11.42",
                        "rate_95_CI": "(7.45\u201317.52)",
                        "p_value": "< 0.001"
                    },
                    "measures": "[no_of_event, person_year_follow_up, rate_per_100_person_year]",
                    "outcomes": "[21, 184, 11.42]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "event_type": "Composite endpoint",
                        "total_events": "692",
                        "current_CD4_CD8_ratio": "0.30\u20130.45",
                        "no_of_event": "28",
                        "person_year_follow_up": "496",
                        "rate_per_100_person_year": "5.64",
                        "rate_95_CI": "(3.90\u20138.17)",
                        "p_value": "< 0.001"
                    },
                    "measures": "[no_of_event, person_year_follow_up, rate_per_100_person_year]",
                    "outcomes": "[28, 496, 5.64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "event_type": "Composite endpoint",
                        "total_events": "692",
                        "current_CD4_CD8_ratio": "> 0.45",
                        "no_of_event": "72",
                        "person_year_follow_up": "3227",
                        "rate_per_100_person_year": "2.23",
                        "rate_95_CI": "(1.77\u20132.81)",
                        "p_value": "< 0.001"
                    },
                    "measures": "[no_of_event, person_year_follow_up, rate_per_100_person_year]",
                    "outcomes": "[72, 3227, 2.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 4,
        "total_ground_truth_claims": 4,
        "number_of_matches": 4
    },
    "PMC7522205_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Total",
                        "Patients": "no. (%), 2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "1687 (59.3%)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Reference group": "Yes"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[0, \u2013, \u2013]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Total",
                        "Patients": "no. (%), 2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "1687 (59.3%)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Reference group": "Yes"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[0, \u2013, \u2013]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Total",
                        "Patients": "no. (%), 2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[139, 117\u2013161, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Total",
                        "Patients": "no. (%), 2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[113, 86\u2013140, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Total",
                        "Patients": "no. (%), 2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "728 (25.6%)",
                        "CD4+ median (IQR)": "205 (108\u2013327)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[94, 73\u2013115, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Total",
                        "Patients": "no. (%), 2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "728 (25.6%)",
                        "CD4+ median (IQR)": "205 (108\u2013327)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[80, 65\u201395, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Total",
                        "Patients": "no. (%), 2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "176 (6.2%)",
                        "CD4+ median (IQR)": "198 (89\u2013355)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[87, 46\u2013128, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Total",
                        "Patients": "no. (%), 2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "176 (6.2%)",
                        "CD4+ median (IQR)": "198 (89\u2013355)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[72, 37\u2013107, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "no. (%), 1687 (59.3)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Unadjusted Coefficient": "0",
                        "Adjusted Coefficient": "0",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "1687 (59.3%)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Reference group": "Yes"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[0, \u2013, \u2013]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "no. (%), 254 (8.9)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Unadjusted Coefficient": "139",
                        "Unadjusted 95% CI": "(117\u2013161)",
                        "Unadjusted P": "<0.001",
                        "Adjusted Coefficient": "113",
                        "Adjusted 95% CI": "(86\u2013140)",
                        "Adjusted P": "<0.001",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
                    "outcomes": "[139, (117\u2013161), <0.001, 113, (86\u2013140), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "1687 (59.3%)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Reference group": "Yes"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[0, \u2013, \u2013]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "no. (%), 254 (8.9)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Unadjusted Coefficient": "139",
                        "Unadjusted 95% CI": "(117\u2013161)",
                        "Unadjusted P": "<0.001",
                        "Adjusted Coefficient": "113",
                        "Adjusted 95% CI": "(86\u2013140)",
                        "Adjusted P": "<0.001",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
                    "outcomes": "[139, (117\u2013161), <0.001, 113, (86\u2013140), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[139, 117\u2013161, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "no. (%), 254 (8.9)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Unadjusted Coefficient": "139",
                        "Unadjusted 95% CI": "(117\u2013161)",
                        "Unadjusted P": "<0.001",
                        "Adjusted Coefficient": "113",
                        "Adjusted 95% CI": "(86\u2013140)",
                        "Adjusted P": "<0.001",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
                    "outcomes": "[139, (117\u2013161), <0.001, 113, (86\u2013140), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[113, 86\u2013140, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "no. (%), 254 (8.9)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Unadjusted Coefficient": "139",
                        "Unadjusted 95% CI": "(117\u2013161)",
                        "Unadjusted P": "<0.001",
                        "Adjusted Coefficient": "113",
                        "Adjusted 95% CI": "(86\u2013140)",
                        "Adjusted P": "<0.001",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
                    "outcomes": "[139, (117\u2013161), <0.001, 113, (86\u2013140), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "728 (25.6%)",
                        "CD4+ median (IQR)": "205 (108\u2013327)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[94, 73\u2013115, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "no. (%), 254 (8.9)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Unadjusted Coefficient": "139",
                        "Unadjusted 95% CI": "(117\u2013161)",
                        "Unadjusted P": "<0.001",
                        "Adjusted Coefficient": "113",
                        "Adjusted 95% CI": "(86\u2013140)",
                        "Adjusted P": "<0.001",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
                    "outcomes": "[139, (117\u2013161), <0.001, 113, (86\u2013140), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "728 (25.6%)",
                        "CD4+ median (IQR)": "205 (108\u2013327)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[80, 65\u201395, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "no. (%), 254 (8.9)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Unadjusted Coefficient": "139",
                        "Unadjusted 95% CI": "(117\u2013161)",
                        "Unadjusted P": "<0.001",
                        "Adjusted Coefficient": "113",
                        "Adjusted 95% CI": "(86\u2013140)",
                        "Adjusted P": "<0.001",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
                    "outcomes": "[139, (117\u2013161), <0.001, 113, (86\u2013140), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "176 (6.2%)",
                        "CD4+ median (IQR)": "198 (89\u2013355)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[87, 46\u2013128, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "no. (%), 254 (8.9)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Unadjusted Coefficient": "139",
                        "Unadjusted 95% CI": "(117\u2013161)",
                        "Unadjusted P": "<0.001",
                        "Adjusted Coefficient": "113",
                        "Adjusted 95% CI": "(86\u2013140)",
                        "Adjusted P": "<0.001",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
                    "outcomes": "[139, (117\u2013161), <0.001, 113, (86\u2013140), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "176 (6.2%)",
                        "CD4+ median (IQR)": "198 (89\u2013355)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[72, 37\u2013107, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "no. (%), 728 (25.6)",
                        "CD4+ median (IQR)": "205 (108\u2013327)",
                        "Unadjusted Coefficient": "94",
                        "Unadjusted 95% CI": "(73\u2013115)",
                        "Unadjusted P": "<0.001",
                        "Adjusted Coefficient": "80",
                        "Adjusted 95% CI": "(65\u201395)",
                        "Adjusted P": "<0.001",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
                    "outcomes": "[94, (73\u2013115), <0.001, 80, (65\u201395), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "1687 (59.3%)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Reference group": "Yes"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[0, \u2013, \u2013]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "no. (%), 728 (25.6)",
                        "CD4+ median (IQR)": "205 (108\u2013327)",
                        "Unadjusted Coefficient": "94",
                        "Unadjusted 95% CI": "(73\u2013115)",
                        "Unadjusted P": "<0.001",
                        "Adjusted Coefficient": "80",
                        "Adjusted 95% CI": "(65\u201395)",
                        "Adjusted P": "<0.001",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
                    "outcomes": "[94, (73\u2013115), <0.001, 80, (65\u201395), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[139, 117\u2013161, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "no. (%), 728 (25.6)",
                        "CD4+ median (IQR)": "205 (108\u2013327)",
                        "Unadjusted Coefficient": "94",
                        "Unadjusted 95% CI": "(73\u2013115)",
                        "Unadjusted P": "<0.001",
                        "Adjusted Coefficient": "80",
                        "Adjusted 95% CI": "(65\u201395)",
                        "Adjusted P": "<0.001",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
                    "outcomes": "[94, (73\u2013115), <0.001, 80, (65\u201395), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[113, 86\u2013140, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "no. (%), 728 (25.6)",
                        "CD4+ median (IQR)": "205 (108\u2013327)",
                        "Unadjusted Coefficient": "94",
                        "Unadjusted 95% CI": "(73\u2013115)",
                        "Unadjusted P": "<0.001",
                        "Adjusted Coefficient": "80",
                        "Adjusted 95% CI": "(65\u201395)",
                        "Adjusted P": "<0.001",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
                    "outcomes": "[94, (73\u2013115), <0.001, 80, (65\u201395), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "728 (25.6%)",
                        "CD4+ median (IQR)": "205 (108\u2013327)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[94, 73\u2013115, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "no. (%), 728 (25.6)",
                        "CD4+ median (IQR)": "205 (108\u2013327)",
                        "Unadjusted Coefficient": "94",
                        "Unadjusted 95% CI": "(73\u2013115)",
                        "Unadjusted P": "<0.001",
                        "Adjusted Coefficient": "80",
                        "Adjusted 95% CI": "(65\u201395)",
                        "Adjusted P": "<0.001",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
                    "outcomes": "[94, (73\u2013115), <0.001, 80, (65\u201395), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "728 (25.6%)",
                        "CD4+ median (IQR)": "205 (108\u2013327)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[80, 65\u201395, <0.001]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "no. (%), 176 (6.2)",
                        "CD4+ median (IQR)": "198 (89\u2013355)",
                        "Unadjusted Coefficient": "87",
                        "Unadjusted 95% CI": "(46\u2013128)",
                        "Unadjusted P": "<0.001",
                        "Adjusted Coefficient": "72",
                        "Adjusted 95% CI": "(37\u2013107)",
                        "Adjusted P": "<0.001",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
                    "outcomes": "[87, (46\u2013128), <0.001, 72, (37\u2013107), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "1687 (59.3%)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Reference group": "Yes"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[0, \u2013, \u2013]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "no. (%), 176 (6.2)",
                        "CD4+ median (IQR)": "198 (89\u2013355)",
                        "Unadjusted Coefficient": "87",
                        "Unadjusted 95% CI": "(46\u2013128)",
                        "Unadjusted P": "<0.001",
                        "Adjusted Coefficient": "72",
                        "Adjusted 95% CI": "(37\u2013107)",
                        "Adjusted P": "<0.001",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
                    "outcomes": "[87, (46\u2013128), <0.001, 72, (37\u2013107), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[139, 117\u2013161, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "no. (%), 176 (6.2)",
                        "CD4+ median (IQR)": "198 (89\u2013355)",
                        "Unadjusted Coefficient": "87",
                        "Unadjusted 95% CI": "(46\u2013128)",
                        "Unadjusted P": "<0.001",
                        "Adjusted Coefficient": "72",
                        "Adjusted 95% CI": "(37\u2013107)",
                        "Adjusted P": "<0.001",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
                    "outcomes": "[87, (46\u2013128), <0.001, 72, (37\u2013107), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[113, 86\u2013140, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "no. (%), 176 (6.2)",
                        "CD4+ median (IQR)": "198 (89\u2013355)",
                        "Unadjusted Coefficient": "87",
                        "Unadjusted 95% CI": "(46\u2013128)",
                        "Unadjusted P": "<0.001",
                        "Adjusted Coefficient": "72",
                        "Adjusted 95% CI": "(37\u2013107)",
                        "Adjusted P": "<0.001",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
                    "outcomes": "[87, (46\u2013128), <0.001, 72, (37\u2013107), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "728 (25.6%)",
                        "CD4+ median (IQR)": "205 (108\u2013327)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[94, 73\u2013115, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "no. (%), 176 (6.2)",
                        "CD4+ median (IQR)": "198 (89\u2013355)",
                        "Unadjusted Coefficient": "87",
                        "Unadjusted 95% CI": "(46\u2013128)",
                        "Unadjusted P": "<0.001",
                        "Adjusted Coefficient": "72",
                        "Adjusted 95% CI": "(37\u2013107)",
                        "Adjusted P": "<0.001",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
                    "outcomes": "[87, (46\u2013128), <0.001, 72, (37\u2013107), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "176 (6.2%)",
                        "CD4+ median (IQR)": "198 (89\u2013355)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[87, 46\u2013128, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "no. (%), 176 (6.2)",
                        "CD4+ median (IQR)": "198 (89\u2013355)",
                        "Unadjusted Coefficient": "87",
                        "Unadjusted 95% CI": "(46\u2013128)",
                        "Unadjusted P": "<0.001",
                        "Adjusted Coefficient": "72",
                        "Adjusted 95% CI": "(37\u2013107)",
                        "Adjusted P": "<0.001",
                        "Study Population": "Newly diagnosed HIV patients",
                        "Context": "Baseline CD4+ cell counts",
                        "Source": "Table 2",
                        "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
                    "outcomes": "[87, (46\u2013128), <0.001, 72, (37\u2013107), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "176 (6.2%)",
                        "CD4+ median (IQR)": "198 (89\u2013355)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[72, 37\u2013107, <0.001]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 5,
        "total_ground_truth_claims": 8,
        "number_of_matches": 3
    },
    "PMC7414801_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "381",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[381, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "114",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[114, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "43",
                        "percentage": "11"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[43, 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "382",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[382, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "115",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[115, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "73",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[73, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "44",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[44, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "26",
                        "percentage": "7"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[26, 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "as-randomized",
                        "total_participants": "382",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "17",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[17, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "HIV VL",
                        "participants": "330",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[330, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "HIV VL",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "HIV VL",
                        "participants": "65",
                        "percentage": "20"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[65, 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "HIV VL",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "HIV VL",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "HIV VL",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "HIV detection visit",
                        "measure": "CD4",
                        "participants": "331",
                        "percentage": "100"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[331, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M3",
                        "measure": "CD4",
                        "participants": "99",
                        "percentage": "30"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[99, 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M6",
                        "measure": "CD4",
                        "participants": "64",
                        "percentage": "19"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[64, 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M9",
                        "measure": "CD4",
                        "participants": "40",
                        "percentage": "12"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[40, 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M12",
                        "measure": "CD4",
                        "participants": "25",
                        "percentage": "8"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[25, 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis_group": "continuous use",
                        "total_participants": "331",
                        "excluded_participants": "women infected at baseline and visits following ART initiation",
                        "timepoint": "M15",
                        "measure": "CD4",
                        "participants": "14",
                        "percentage": "4"
                    },
                    "measures": "[participants, percentage]",
                    "outcomes": "[14, 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 24,
        "total_ground_truth_claims": 30,
        "number_of_matches": 2
    },
    "PMC9624454_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "All children",
                        "No.": "1024",
                        "CMV Viremia": "314 (30.7)",
                        "CMV Viremia \u2264 1000 IU/mL": "59 (5.8)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[CMV Viremia (%)]",
                    "outcomes": "[30.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "All children",
                        "No.": "1024",
                        "CMV Viremia": "314 (30.7)",
                        "CMV Viremia \u2264 1000 IU/mL": "59 (5.8)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%)]",
                    "outcomes": "[5.8%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "All children",
                        "No.": "1024",
                        "CMV Viremia": "314 (30.7)",
                        "CMV Viremia \u2264 1000 IU/mL": "59 (5.8)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "All children",
                        "No.": "1024",
                        "CMV Viremia": "314 (30.7)",
                        "CMV Viremia \u2264 1000 IU/mL": "59 (5.8)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[CMV Viremia (%)]",
                    "outcomes": "[29.0%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "All children",
                        "No.": "1024",
                        "CMV Viremia": "314 (30.7)",
                        "CMV Viremia \u2264 1000 IU/mL": "59 (5.8)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%)]",
                    "outcomes": "[5.2%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "All children",
                        "No.": "1024",
                        "CMV Viremia": "314 (30.7)",
                        "CMV Viremia \u2264 1000 IU/mL": "59 (5.8)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "All children",
                        "No.": "1024",
                        "CMV Viremia": "314 (30.7)",
                        "CMV Viremia \u2264 1000 IU/mL": "59 (5.8)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[38.1%, 0.061]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "All children",
                        "No.": "1024",
                        "CMV Viremia": "314 (30.7)",
                        "CMV Viremia \u2264 1000 IU/mL": "59 (5.8)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[8.5%, 0.18]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "All children",
                        "No.": "1024",
                        "CMV Viremia": "314 (30.7)",
                        "CMV Viremia \u2264 1000 IU/mL": "59 (5.8)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[2.4 (2.0\u20132.9), 0.24]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "All children",
                        "No.": "1024",
                        "CMV Viremia": "314 (30.7)",
                        "CMV Viremia \u2264 1000 IU/mL": "59 (5.8)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[37.1%, 0.088]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "All children",
                        "No.": "1024",
                        "CMV Viremia": "314 (30.7)",
                        "CMV Viremia \u2264 1000 IU/mL": "59 (5.8)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[6.2%, 0.56]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "All children",
                        "No.": "1024",
                        "CMV Viremia": "314 (30.7)",
                        "CMV Viremia \u2264 1000 IU/mL": "59 (5.8)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[2.4 (1.9\u20132.7), 0.74]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "All children",
                        "No.": "1024",
                        "CMV Viremia": "314 (30.7)",
                        "CMV Viremia \u2264 1000 IU/mL": "59 (5.8)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[40.0%, 0.39]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "All children",
                        "No.": "1024",
                        "CMV Viremia": "314 (30.7)",
                        "CMV Viremia \u2264 1000 IU/mL": "59 (5.8)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[20.0%, 0.015]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "All children",
                        "No.": "1024",
                        "CMV Viremia": "314 (30.7)",
                        "CMV Viremia \u2264 1000 IU/mL": "59 (5.8)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[3.2 (2.6\u20135.3), 0.012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV unexposed",
                        "No.": "872",
                        "CMV Viremia": "253 (29.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "45 (5.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[253 (29.0), 45 (5.2), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[CMV Viremia (%)]",
                    "outcomes": "[30.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV unexposed",
                        "No.": "872",
                        "CMV Viremia": "253 (29.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "45 (5.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[253 (29.0), 45 (5.2), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%)]",
                    "outcomes": "[5.8%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV unexposed",
                        "No.": "872",
                        "CMV Viremia": "253 (29.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "45 (5.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[253 (29.0), 45 (5.2), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV unexposed",
                        "No.": "872",
                        "CMV Viremia": "253 (29.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "45 (5.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[253 (29.0), 45 (5.2), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[CMV Viremia (%)]",
                    "outcomes": "[29.0%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV unexposed",
                        "No.": "872",
                        "CMV Viremia": "253 (29.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "45 (5.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[253 (29.0), 45 (5.2), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%)]",
                    "outcomes": "[5.2%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV unexposed",
                        "No.": "872",
                        "CMV Viremia": "253 (29.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "45 (5.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[253 (29.0), 45 (5.2), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV unexposed",
                        "No.": "872",
                        "CMV Viremia": "253 (29.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "45 (5.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[253 (29.0), 45 (5.2), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[38.1%, 0.061]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV unexposed",
                        "No.": "872",
                        "CMV Viremia": "253 (29.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "45 (5.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[253 (29.0), 45 (5.2), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[8.5%, 0.18]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV unexposed",
                        "No.": "872",
                        "CMV Viremia": "253 (29.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "45 (5.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[253 (29.0), 45 (5.2), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[2.4 (2.0\u20132.9), 0.24]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV unexposed",
                        "No.": "872",
                        "CMV Viremia": "253 (29.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "45 (5.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[253 (29.0), 45 (5.2), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[37.1%, 0.088]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV unexposed",
                        "No.": "872",
                        "CMV Viremia": "253 (29.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "45 (5.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[253 (29.0), 45 (5.2), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[6.2%, 0.56]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV unexposed",
                        "No.": "872",
                        "CMV Viremia": "253 (29.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "45 (5.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[253 (29.0), 45 (5.2), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[2.4 (1.9\u20132.7), 0.74]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV unexposed",
                        "No.": "872",
                        "CMV Viremia": "253 (29.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "45 (5.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[253 (29.0), 45 (5.2), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[40.0%, 0.39]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV unexposed",
                        "No.": "872",
                        "CMV Viremia": "253 (29.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "45 (5.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[253 (29.0), 45 (5.2), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[20.0%, 0.015]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV unexposed",
                        "No.": "872",
                        "CMV Viremia": "253 (29.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "45 (5.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[253 (29.0), 45 (5.2), 2.3 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[3.2 (2.6\u20135.3), 0.012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed",
                        "No.": "118",
                        "CMV Viremia": "45 (38.1)",
                        "P Value (CMV Viremia)": ".061",
                        "CMV Viremia \u2264 1000 IU/mL": "10 (8.5)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".18",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (2.0\u20132.9)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".24",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[45 (38.1), 10 (8.5), 2.4 (2.0\u20132.9)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[CMV Viremia (%)]",
                    "outcomes": "[30.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed",
                        "No.": "118",
                        "CMV Viremia": "45 (38.1)",
                        "P Value (CMV Viremia)": ".061",
                        "CMV Viremia \u2264 1000 IU/mL": "10 (8.5)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".18",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (2.0\u20132.9)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".24",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[45 (38.1), 10 (8.5), 2.4 (2.0\u20132.9)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%)]",
                    "outcomes": "[5.8%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed",
                        "No.": "118",
                        "CMV Viremia": "45 (38.1)",
                        "P Value (CMV Viremia)": ".061",
                        "CMV Viremia \u2264 1000 IU/mL": "10 (8.5)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".18",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (2.0\u20132.9)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".24",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[45 (38.1), 10 (8.5), 2.4 (2.0\u20132.9)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed",
                        "No.": "118",
                        "CMV Viremia": "45 (38.1)",
                        "P Value (CMV Viremia)": ".061",
                        "CMV Viremia \u2264 1000 IU/mL": "10 (8.5)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".18",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (2.0\u20132.9)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".24",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[45 (38.1), 10 (8.5), 2.4 (2.0\u20132.9)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[CMV Viremia (%)]",
                    "outcomes": "[29.0%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed",
                        "No.": "118",
                        "CMV Viremia": "45 (38.1)",
                        "P Value (CMV Viremia)": ".061",
                        "CMV Viremia \u2264 1000 IU/mL": "10 (8.5)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".18",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (2.0\u20132.9)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".24",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[45 (38.1), 10 (8.5), 2.4 (2.0\u20132.9)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%)]",
                    "outcomes": "[5.2%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed",
                        "No.": "118",
                        "CMV Viremia": "45 (38.1)",
                        "P Value (CMV Viremia)": ".061",
                        "CMV Viremia \u2264 1000 IU/mL": "10 (8.5)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".18",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (2.0\u20132.9)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".24",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[45 (38.1), 10 (8.5), 2.4 (2.0\u20132.9)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed",
                        "No.": "118",
                        "CMV Viremia": "45 (38.1)",
                        "P Value (CMV Viremia)": ".061",
                        "CMV Viremia \u2264 1000 IU/mL": "10 (8.5)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".18",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (2.0\u20132.9)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".24",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[45 (38.1), 10 (8.5), 2.4 (2.0\u20132.9)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[38.1%, 0.061]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed",
                        "No.": "118",
                        "CMV Viremia": "45 (38.1)",
                        "P Value (CMV Viremia)": ".061",
                        "CMV Viremia \u2264 1000 IU/mL": "10 (8.5)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".18",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (2.0\u20132.9)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".24",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[45 (38.1), 10 (8.5), 2.4 (2.0\u20132.9)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[8.5%, 0.18]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed",
                        "No.": "118",
                        "CMV Viremia": "45 (38.1)",
                        "P Value (CMV Viremia)": ".061",
                        "CMV Viremia \u2264 1000 IU/mL": "10 (8.5)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".18",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (2.0\u20132.9)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".24",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[45 (38.1), 10 (8.5), 2.4 (2.0\u20132.9)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[2.4 (2.0\u20132.9), 0.24]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed uninfected",
                        "No.": "97",
                        "CMV Viremia": "36 (37.1)",
                        "P Value (CMV Viremia)": ".088",
                        "CMV Viremia \u2264 1000 IU/mL": "6 (6.2)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".56",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".74",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[36 (37.1), 6 (6.2), 2.4 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[CMV Viremia (%)]",
                    "outcomes": "[30.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed uninfected",
                        "No.": "97",
                        "CMV Viremia": "36 (37.1)",
                        "P Value (CMV Viremia)": ".088",
                        "CMV Viremia \u2264 1000 IU/mL": "6 (6.2)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".56",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".74",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[36 (37.1), 6 (6.2), 2.4 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%)]",
                    "outcomes": "[5.8%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed uninfected",
                        "No.": "97",
                        "CMV Viremia": "36 (37.1)",
                        "P Value (CMV Viremia)": ".088",
                        "CMV Viremia \u2264 1000 IU/mL": "6 (6.2)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".56",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".74",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[36 (37.1), 6 (6.2), 2.4 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed uninfected",
                        "No.": "97",
                        "CMV Viremia": "36 (37.1)",
                        "P Value (CMV Viremia)": ".088",
                        "CMV Viremia \u2264 1000 IU/mL": "6 (6.2)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".56",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".74",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[36 (37.1), 6 (6.2), 2.4 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[CMV Viremia (%)]",
                    "outcomes": "[29.0%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed uninfected",
                        "No.": "97",
                        "CMV Viremia": "36 (37.1)",
                        "P Value (CMV Viremia)": ".088",
                        "CMV Viremia \u2264 1000 IU/mL": "6 (6.2)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".56",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".74",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[36 (37.1), 6 (6.2), 2.4 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%)]",
                    "outcomes": "[5.2%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed uninfected",
                        "No.": "97",
                        "CMV Viremia": "36 (37.1)",
                        "P Value (CMV Viremia)": ".088",
                        "CMV Viremia \u2264 1000 IU/mL": "6 (6.2)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".56",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".74",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[36 (37.1), 6 (6.2), 2.4 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed uninfected",
                        "No.": "97",
                        "CMV Viremia": "36 (37.1)",
                        "P Value (CMV Viremia)": ".088",
                        "CMV Viremia \u2264 1000 IU/mL": "6 (6.2)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".56",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".74",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[36 (37.1), 6 (6.2), 2.4 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[38.1%, 0.061]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed uninfected",
                        "No.": "97",
                        "CMV Viremia": "36 (37.1)",
                        "P Value (CMV Viremia)": ".088",
                        "CMV Viremia \u2264 1000 IU/mL": "6 (6.2)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".56",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".74",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[36 (37.1), 6 (6.2), 2.4 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[8.5%, 0.18]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed uninfected",
                        "No.": "97",
                        "CMV Viremia": "36 (37.1)",
                        "P Value (CMV Viremia)": ".088",
                        "CMV Viremia \u2264 1000 IU/mL": "6 (6.2)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".56",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".74",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[36 (37.1), 6 (6.2), 2.4 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[37.1%, 0.088]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed uninfected",
                        "No.": "97",
                        "CMV Viremia": "36 (37.1)",
                        "P Value (CMV Viremia)": ".088",
                        "CMV Viremia \u2264 1000 IU/mL": "6 (6.2)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".56",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".74",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[36 (37.1), 6 (6.2), 2.4 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[6.2%, 0.56]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed uninfected",
                        "No.": "97",
                        "CMV Viremia": "36 (37.1)",
                        "P Value (CMV Viremia)": ".088",
                        "CMV Viremia \u2264 1000 IU/mL": "6 (6.2)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".56",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".74",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[36 (37.1), 6 (6.2), 2.4 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[2.4 (1.9\u20132.7), 0.74]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed uninfected",
                        "No.": "97",
                        "CMV Viremia": "36 (37.1)",
                        "P Value (CMV Viremia)": ".088",
                        "CMV Viremia \u2264 1000 IU/mL": "6 (6.2)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".56",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".74",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[36 (37.1), 6 (6.2), 2.4 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[40.0%, 0.39]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed uninfected",
                        "No.": "97",
                        "CMV Viremia": "36 (37.1)",
                        "P Value (CMV Viremia)": ".088",
                        "CMV Viremia \u2264 1000 IU/mL": "6 (6.2)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".56",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".74",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[36 (37.1), 6 (6.2), 2.4 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[20.0%, 0.015]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed uninfected",
                        "No.": "97",
                        "CMV Viremia": "36 (37.1)",
                        "P Value (CMV Viremia)": ".088",
                        "CMV Viremia \u2264 1000 IU/mL": "6 (6.2)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".56",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".74",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[36 (37.1), 6 (6.2), 2.4 (1.9\u20132.7)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[3.2 (2.6\u20135.3), 0.012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "6 (40.0)",
                        "P Value (CMV Viremia)": ".39",
                        "CMV Viremia \u2264 1000 IU/mL": "3 (20.0)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".015",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".012",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[6 (40.0), 3 (20.0), 3.2 (2.6\u20135.3)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[CMV Viremia (%)]",
                    "outcomes": "[30.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "6 (40.0)",
                        "P Value (CMV Viremia)": ".39",
                        "CMV Viremia \u2264 1000 IU/mL": "3 (20.0)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".015",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".012",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[6 (40.0), 3 (20.0), 3.2 (2.6\u20135.3)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%)]",
                    "outcomes": "[5.8%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "6 (40.0)",
                        "P Value (CMV Viremia)": ".39",
                        "CMV Viremia \u2264 1000 IU/mL": "3 (20.0)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".015",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".012",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[6 (40.0), 3 (20.0), 3.2 (2.6\u20135.3)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "6 (40.0)",
                        "P Value (CMV Viremia)": ".39",
                        "CMV Viremia \u2264 1000 IU/mL": "3 (20.0)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".015",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".012",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[6 (40.0), 3 (20.0), 3.2 (2.6\u20135.3)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[CMV Viremia (%)]",
                    "outcomes": "[29.0%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "6 (40.0)",
                        "P Value (CMV Viremia)": ".39",
                        "CMV Viremia \u2264 1000 IU/mL": "3 (20.0)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".015",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".012",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[6 (40.0), 3 (20.0), 3.2 (2.6\u20135.3)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%)]",
                    "outcomes": "[5.2%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "6 (40.0)",
                        "P Value (CMV Viremia)": ".39",
                        "CMV Viremia \u2264 1000 IU/mL": "3 (20.0)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".015",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".012",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[6 (40.0), 3 (20.0), 3.2 (2.6\u20135.3)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "6 (40.0)",
                        "P Value (CMV Viremia)": ".39",
                        "CMV Viremia \u2264 1000 IU/mL": "3 (20.0)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".015",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".012",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[6 (40.0), 3 (20.0), 3.2 (2.6\u20135.3)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[38.1%, 0.061]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "6 (40.0)",
                        "P Value (CMV Viremia)": ".39",
                        "CMV Viremia \u2264 1000 IU/mL": "3 (20.0)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".015",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".012",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[6 (40.0), 3 (20.0), 3.2 (2.6\u20135.3)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[8.5%, 0.18]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "6 (40.0)",
                        "P Value (CMV Viremia)": ".39",
                        "CMV Viremia \u2264 1000 IU/mL": "3 (20.0)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".015",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".012",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[6 (40.0), 3 (20.0), 3.2 (2.6\u20135.3)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[37.1%, 0.088]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "6 (40.0)",
                        "P Value (CMV Viremia)": ".39",
                        "CMV Viremia \u2264 1000 IU/mL": "3 (20.0)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".015",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".012",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[6 (40.0), 3 (20.0), 3.2 (2.6\u20135.3)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[6.2%, 0.56]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "6 (40.0)",
                        "P Value (CMV Viremia)": ".39",
                        "CMV Viremia \u2264 1000 IU/mL": "3 (20.0)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".015",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".012",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[6 (40.0), 3 (20.0), 3.2 (2.6\u20135.3)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[2.4 (1.9\u20132.7), 0.74]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "6 (40.0)",
                        "P Value (CMV Viremia)": ".39",
                        "CMV Viremia \u2264 1000 IU/mL": "3 (20.0)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".015",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".012",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[6 (40.0), 3 (20.0), 3.2 (2.6\u20135.3)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[40.0%, 0.39]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "6 (40.0)",
                        "P Value (CMV Viremia)": ".39",
                        "CMV Viremia \u2264 1000 IU/mL": "3 (20.0)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".015",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".012",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[6 (40.0), 3 (20.0), 3.2 (2.6\u20135.3)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[20.0%, 0.015]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "6 (40.0)",
                        "P Value (CMV Viremia)": ".39",
                        "CMV Viremia \u2264 1000 IU/mL": "3 (20.0)",
                        "P Value (CMV Viremia \u2264 1000 IU/mL)": ".015",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "P Value (log10 CMV IU/mL in Viremics)": ".012",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
                    "outcomes": "[6 (40.0), 3 (20.0), 3.2 (2.6\u20135.3)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[3.2 (2.6\u20135.3), 0.012]"
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 5,
        "total_ground_truth_claims": 15,
        "number_of_matches": 1
    },
    "PMC4549947_4": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "females",
                        "race/ethnicity": "unspecified",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[1.3]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "gender": "females",
                        "p-interaction": "0.35"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.3]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "males",
                        "race/ethnicity": "unspecified",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[3.5, p = 0.008]",
                    "outcomes": "[1.5\u20135.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "gender": "males",
                        "p-interaction": "0.35"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[3.5, 1.5\u20135.5, 0.008]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "unspecified",
                        "race/ethnicity": "Hispanics",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[2.6]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "unspecified",
                        "race/ethnicity": "African American",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[3.1, p = 0.01]",
                    "outcomes": "[2.3\u20133.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[3.1, 2.3\u20133.5, 0.01]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "unspecified",
                        "race/ethnicity": "unspecified",
                        "alcohol use": "yes",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[2.6]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "context": "alcohol use"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "females",
                        "race/ethnicity": "unspecified",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[p_interaction = 0.35]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "females",
                        "p-intraction": "0.013"
                    },
                    "measures": "[OR]",
                    "outcomes": "[0.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "females",
                        "race/ethnicity": "unspecified",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[p_interaction = 0.35]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "males",
                        "p-interaction": "0.013"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.8, 1.2\u20132.9, 0.01]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "females",
                        "race/ethnicity": "unspecified",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[p_interaction = 0.35]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "females",
                        "race/ethnicity": "unspecified",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[p_interaction = 0.35]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "females",
                        "race/ethnicity": "unspecified",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[p_interaction = 0.35]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "context": "alcohol use",
                        "p-interaction": "0.32"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.6, 1.4\u20132.4, 0.03]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "males",
                        "race/ethnicity": "unspecified",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[p_interaction = 0.35]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "females",
                        "p-intraction": "0.013"
                    },
                    "measures": "[OR]",
                    "outcomes": "[0.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "males",
                        "race/ethnicity": "unspecified",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[p_interaction = 0.35]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "males",
                        "p-interaction": "0.013"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.8, 1.2\u20132.9, 0.01]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "males",
                        "race/ethnicity": "unspecified",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[p_interaction = 0.35]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "males",
                        "race/ethnicity": "unspecified",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[p_interaction = 0.35]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "males",
                        "race/ethnicity": "unspecified",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[p_interaction = 0.35]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "context": "alcohol use",
                        "p-interaction": "0.32"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.6, 1.4\u20132.4, 0.03]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "unspecified",
                        "race/ethnicity": "Hispanics",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[p_interaction = 0.05]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "females",
                        "p-intraction": "0.013"
                    },
                    "measures": "[OR]",
                    "outcomes": "[0.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "unspecified",
                        "race/ethnicity": "Hispanics",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[p_interaction = 0.05]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "males",
                        "p-interaction": "0.013"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.8, 1.2\u20132.9, 0.01]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "unspecified",
                        "race/ethnicity": "Hispanics",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[p_interaction = 0.05]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "unspecified",
                        "race/ethnicity": "Hispanics",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[p_interaction = 0.05]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "unspecified",
                        "race/ethnicity": "Hispanics",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[p_interaction = 0.05]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "context": "alcohol use",
                        "p-interaction": "0.32"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.6, 1.4\u20132.4, 0.03]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "unspecified",
                        "race/ethnicity": "African American",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[p_interaction = 0.05]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "females",
                        "p-intraction": "0.013"
                    },
                    "measures": "[OR]",
                    "outcomes": "[0.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "unspecified",
                        "race/ethnicity": "African American",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[p_interaction = 0.05]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "males",
                        "p-interaction": "0.013"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.8, 1.2\u20132.9, 0.01]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "unspecified",
                        "race/ethnicity": "African American",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[p_interaction = 0.05]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "unspecified",
                        "race/ethnicity": "African American",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[p_interaction = 0.05]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "executive function",
                        "gender": "unspecified",
                        "race/ethnicity": "African American",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[p_interaction = 0.05]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "context": "alcohol use",
                        "p-interaction": "0.32"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.6, 1.4\u20132.4, 0.03]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "females",
                        "race/ethnicity": "unspecified",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[0.9]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "females",
                        "p-intraction": "0.013"
                    },
                    "measures": "[OR]",
                    "outcomes": "[0.9]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "males",
                        "race/ethnicity": "unspecified",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[1.8, p = 0.01]",
                    "outcomes": "[1.2\u20132.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "males",
                        "p-interaction": "0.013"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.8, 1.2\u20132.9, 0.01]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "unspecified",
                        "race/ethnicity": "Hispanics",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[1.9]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.9]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "unspecified",
                        "race/ethnicity": "African American",
                        "alcohol use": "unspecified",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[1.5]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.5]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "DRD2",
                        "SNP": "rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "unspecified",
                        "race/ethnicity": "unspecified",
                        "alcohol use": "yes",
                        "Hardy\u2013Weinberg equilibrium": "true"
                    },
                    "measures": "[1.6, p = 0.03]",
                    "outcomes": "[1.4\u20132.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "context": "alcohol use",
                        "p-interaction": "0.32"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.6, 1.4\u20132.4, 0.03]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 19,
        "total_ground_truth_claims": 10,
        "number_of_matches": 10
    },
    "PMC6694514_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Hepatobiliary disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "12",
                        "Percentage of total G3+ events in HIV group": "30.0%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Hepatobiliary disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "12",
                        "30.0%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Hepatobiliary disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "15",
                        "Percentage of total G3+ events in HIV group": "25.0%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[15]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Hepatobiliary disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "15",
                        "25.0%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "7",
                        "Percentage of total G3+ events in HIV group": "17.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "7",
                        "Percentage of total G3+ events in HIV group": "17.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "7",
                        "Percentage of total G3+ events in HIV group": "17.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "7",
                        "Percentage of total G3+ events in HIV group": "17.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "7",
                        "Percentage of total G3+ events in HIV group": "17.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "7",
                        "Percentage of total G3+ events in HIV group": "17.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "7",
                        "Percentage of total G3+ events in HIV group": "17.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "7",
                        "Percentage of total G3+ events in HIV group": "17.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "13",
                        "Percentage of total G3+ events in HIV group": "21.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "13",
                        "Percentage of total G3+ events in HIV group": "21.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "13",
                        "Percentage of total G3+ events in HIV group": "21.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "13",
                        "Percentage of total G3+ events in HIV group": "21.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "13",
                        "Percentage of total G3+ events in HIV group": "21.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "13",
                        "Percentage of total G3+ events in HIV group": "21.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "13",
                        "Percentage of total G3+ events in HIV group": "21.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "13",
                        "Percentage of total G3+ events in HIV group": "21.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "6",
                        "Percentage of total G3+ events in HIV group": "15.0%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "6",
                        "Percentage of total G3+ events in HIV group": "15.0%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "6",
                        "Percentage of total G3+ events in HIV group": "15.0%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "6",
                        "Percentage of total G3+ events in HIV group": "15.0%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "6",
                        "Percentage of total G3+ events in HIV group": "15.0%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "6",
                        "Percentage of total G3+ events in HIV group": "15.0%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "6",
                        "Percentage of total G3+ events in HIV group": "15.0%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "6",
                        "Percentage of total G3+ events in HIV group": "15.0%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "10",
                        "Percentage of total G3+ events in HIV group": "16.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[10]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "10",
                        "Percentage of total G3+ events in HIV group": "16.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[10]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "10",
                        "Percentage of total G3+ events in HIV group": "16.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[10]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "10",
                        "Percentage of total G3+ events in HIV group": "16.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[10]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "10",
                        "Percentage of total G3+ events in HIV group": "16.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[10]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "10",
                        "Percentage of total G3+ events in HIV group": "16.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[10]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "10",
                        "Percentage of total G3+ events in HIV group": "16.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[10]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "10",
                        "Percentage of total G3+ events in HIV group": "16.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[10]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "3",
                        "Percentage of total G3+ events in HIV group": "7.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "3",
                        "Percentage of total G3+ events in HIV group": "7.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "3",
                        "Percentage of total G3+ events in HIV group": "7.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "3",
                        "Percentage of total G3+ events in HIV group": "7.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "3",
                        "Percentage of total G3+ events in HIV group": "7.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "3",
                        "Percentage of total G3+ events in HIV group": "7.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "3",
                        "Percentage of total G3+ events in HIV group": "7.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "3",
                        "Percentage of total G3+ events in HIV group": "7.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "5",
                        "Percentage of total G3+ events in HIV group": "8.3%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "5",
                        "Percentage of total G3+ events in HIV group": "8.3%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "5",
                        "Percentage of total G3+ events in HIV group": "8.3%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "5",
                        "Percentage of total G3+ events in HIV group": "8.3%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "5",
                        "Percentage of total G3+ events in HIV group": "8.3%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "5",
                        "Percentage of total G3+ events in HIV group": "8.3%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "5",
                        "Percentage of total G3+ events in HIV group": "8.3%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "5",
                        "Percentage of total G3+ events in HIV group": "8.3%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "3",
                        "Percentage of total G3+ events in HIV group": "7.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "3",
                        "Percentage of total G3+ events in HIV group": "7.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "3",
                        "Percentage of total G3+ events in HIV group": "7.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "3",
                        "Percentage of total G3+ events in HIV group": "7.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "3",
                        "Percentage of total G3+ events in HIV group": "7.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "3",
                        "Percentage of total G3+ events in HIV group": "7.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "3",
                        "Percentage of total G3+ events in HIV group": "7.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "3",
                        "Percentage of total G3+ events in HIV group": "7.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "4",
                        "Percentage of total G3+ events in HIV group": "6.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "4",
                        "Percentage of total G3+ events in HIV group": "6.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "4",
                        "Percentage of total G3+ events in HIV group": "6.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "4",
                        "Percentage of total G3+ events in HIV group": "6.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "4",
                        "Percentage of total G3+ events in HIV group": "6.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "4",
                        "Percentage of total G3+ events in HIV group": "6.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "4",
                        "Percentage of total G3+ events in HIV group": "6.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "4",
                        "Percentage of total G3+ events in HIV group": "6.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "9",
                        "Percentage of total G3+ events in HIV group": "17.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "9",
                        "Percentage of total G3+ events in HIV group": "17.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "9",
                        "Percentage of total G3+ events in HIV group": "17.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "9",
                        "Percentage of total G3+ events in HIV group": "17.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "9",
                        "Percentage of total G3+ events in HIV group": "17.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "9",
                        "Percentage of total G3+ events in HIV group": "17.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "9",
                        "Percentage of total G3+ events in HIV group": "17.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "9",
                        "Percentage of total G3+ events in HIV group": "17.5%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "13",
                        "Percentage of total G3+ events in HIV group": "16.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "13",
                        "Percentage of total G3+ events in HIV group": "16.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "13",
                        "Percentage of total G3+ events in HIV group": "16.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "13",
                        "Percentage of total G3+ events in HIV group": "16.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "13",
                        "Percentage of total G3+ events in HIV group": "16.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "13",
                        "Percentage of total G3+ events in HIV group": "16.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "13",
                        "Percentage of total G3+ events in HIV group": "16.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Event count": "13",
                        "Percentage of total G3+ events in HIV group": "16.7%"
                    },
                    "measures": "[Event count]",
                    "outcomes": "[13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing \u22651 AE": "20",
                        "Percentage of patients experiencing \u22651 AE": "47.6%"
                    },
                    "measures": "[Patients experiencing \u22651 AE]",
                    "outcomes": "[20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing \u22651 AE": "20",
                        "Percentage of patients experiencing \u22651 AE": "47.6%"
                    },
                    "measures": "[Patients experiencing \u22651 AE]",
                    "outcomes": "[20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing \u22651 AE": "20",
                        "Percentage of patients experiencing \u22651 AE": "47.6%"
                    },
                    "measures": "[Patients experiencing \u22651 AE]",
                    "outcomes": "[20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing \u22651 AE": "20",
                        "Percentage of patients experiencing \u22651 AE": "47.6%"
                    },
                    "measures": "[Patients experiencing \u22651 AE]",
                    "outcomes": "[20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing \u22651 AE": "20",
                        "Percentage of patients experiencing \u22651 AE": "47.6%"
                    },
                    "measures": "[Patients experiencing \u22651 AE]",
                    "outcomes": "[20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing \u22651 AE": "20",
                        "Percentage of patients experiencing \u22651 AE": "47.6%"
                    },
                    "measures": "[Patients experiencing \u22651 AE]",
                    "outcomes": "[20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing \u22651 AE": "20",
                        "Percentage of patients experiencing \u22651 AE": "47.6%"
                    },
                    "measures": "[Patients experiencing \u22651 AE]",
                    "outcomes": "[20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing \u22651 AE": "20",
                        "Percentage of patients experiencing \u22651 AE": "47.6%"
                    },
                    "measures": "[Patients experiencing \u22651 AE]",
                    "outcomes": "[20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing \u22651 AE": "34",
                        "Percentage of patients experiencing \u22651 AE": "15.5%"
                    },
                    "measures": "[Patients experiencing \u22651 AE]",
                    "outcomes": "[34]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing \u22651 AE": "34",
                        "Percentage of patients experiencing \u22651 AE": "15.5%"
                    },
                    "measures": "[Patients experiencing \u22651 AE]",
                    "outcomes": "[34]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing \u22651 AE": "34",
                        "Percentage of patients experiencing \u22651 AE": "15.5%"
                    },
                    "measures": "[Patients experiencing \u22651 AE]",
                    "outcomes": "[34]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing \u22651 AE": "34",
                        "Percentage of patients experiencing \u22651 AE": "15.5%"
                    },
                    "measures": "[Patients experiencing \u22651 AE]",
                    "outcomes": "[34]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing \u22651 AE": "34",
                        "Percentage of patients experiencing \u22651 AE": "15.5%"
                    },
                    "measures": "[Patients experiencing \u22651 AE]",
                    "outcomes": "[34]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing \u22651 AE": "34",
                        "Percentage of patients experiencing \u22651 AE": "15.5%"
                    },
                    "measures": "[Patients experiencing \u22651 AE]",
                    "outcomes": "[34]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing \u22651 AE": "34",
                        "Percentage of patients experiencing \u22651 AE": "15.5%"
                    },
                    "measures": "[Patients experiencing \u22651 AE]",
                    "outcomes": "[34]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing \u22651 AE": "34",
                        "Percentage of patients experiencing \u22651 AE": "15.5%"
                    },
                    "measures": "[Patients experiencing \u22651 AE]",
                    "outcomes": "[34]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients with treatment-related AE": "11",
                        "Percentage of patients with treatment-related AE": "26.2%"
                    },
                    "measures": "[Patients with treatment-related AE]",
                    "outcomes": "[11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients with treatment-related AE": "11",
                        "Percentage of patients with treatment-related AE": "26.2%"
                    },
                    "measures": "[Patients with treatment-related AE]",
                    "outcomes": "[11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients with treatment-related AE": "11",
                        "Percentage of patients with treatment-related AE": "26.2%"
                    },
                    "measures": "[Patients with treatment-related AE]",
                    "outcomes": "[11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients with treatment-related AE": "11",
                        "Percentage of patients with treatment-related AE": "26.2%"
                    },
                    "measures": "[Patients with treatment-related AE]",
                    "outcomes": "[11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients with treatment-related AE": "11",
                        "Percentage of patients with treatment-related AE": "26.2%"
                    },
                    "measures": "[Patients with treatment-related AE]",
                    "outcomes": "[11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients with treatment-related AE": "11",
                        "Percentage of patients with treatment-related AE": "26.2%"
                    },
                    "measures": "[Patients with treatment-related AE]",
                    "outcomes": "[11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients with treatment-related AE": "11",
                        "Percentage of patients with treatment-related AE": "26.2%"
                    },
                    "measures": "[Patients with treatment-related AE]",
                    "outcomes": "[11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients with treatment-related AE": "11",
                        "Percentage of patients with treatment-related AE": "26.2%"
                    },
                    "measures": "[Patients with treatment-related AE]",
                    "outcomes": "[11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients with treatment-related AE": "14",
                        "Percentage of patients with treatment-related AE": "6.4%"
                    },
                    "measures": "[Patients with treatment-related AE]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients with treatment-related AE": "14",
                        "Percentage of patients with treatment-related AE": "6.4%"
                    },
                    "measures": "[Patients with treatment-related AE]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients with treatment-related AE": "14",
                        "Percentage of patients with treatment-related AE": "6.4%"
                    },
                    "measures": "[Patients with treatment-related AE]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients with treatment-related AE": "14",
                        "Percentage of patients with treatment-related AE": "6.4%"
                    },
                    "measures": "[Patients with treatment-related AE]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients with treatment-related AE": "14",
                        "Percentage of patients with treatment-related AE": "6.4%"
                    },
                    "measures": "[Patients with treatment-related AE]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients with treatment-related AE": "14",
                        "Percentage of patients with treatment-related AE": "6.4%"
                    },
                    "measures": "[Patients with treatment-related AE]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients with treatment-related AE": "14",
                        "Percentage of patients with treatment-related AE": "6.4%"
                    },
                    "measures": "[Patients with treatment-related AE]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients with treatment-related AE": "14",
                        "Percentage of patients with treatment-related AE": "6.4%"
                    },
                    "measures": "[Patients with treatment-related AE]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Hepatobiliary disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing events": "6",
                        "Percentage of patients experiencing events": "14.3%"
                    },
                    "measures": "[Patients experiencing events]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Hepatobiliary disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing events": "6",
                        "Percentage of patients experiencing events": "14.3%"
                    },
                    "measures": "[Patients experiencing events]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Hepatobiliary disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing events": "6",
                        "Percentage of patients experiencing events": "14.3%"
                    },
                    "measures": "[Patients experiencing events]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Hepatobiliary disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing events": "6",
                        "Percentage of patients experiencing events": "14.3%"
                    },
                    "measures": "[Patients experiencing events]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Hepatobiliary disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing events": "6",
                        "Percentage of patients experiencing events": "14.3%"
                    },
                    "measures": "[Patients experiencing events]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Hepatobiliary disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing events": "6",
                        "Percentage of patients experiencing events": "14.3%"
                    },
                    "measures": "[Patients experiencing events]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Hepatobiliary disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing events": "6",
                        "Percentage of patients experiencing events": "14.3%"
                    },
                    "measures": "[Patients experiencing events]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Hepatobiliary disorders",
                        "HIV status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing events": "6",
                        "Percentage of patients experiencing events": "14.3%"
                    },
                    "measures": "[Patients experiencing events]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Hepatobiliary disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing events": "9",
                        "Percentage of patients experiencing events": "4.1%"
                    },
                    "measures": "[Patients experiencing events]",
                    "outcomes": "[9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Hepatobiliary disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing events": "9",
                        "Percentage of patients experiencing events": "4.1%"
                    },
                    "measures": "[Patients experiencing events]",
                    "outcomes": "[9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Hepatobiliary disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing events": "9",
                        "Percentage of patients experiencing events": "4.1%"
                    },
                    "measures": "[Patients experiencing events]",
                    "outcomes": "[9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Hepatobiliary disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing events": "9",
                        "Percentage of patients experiencing events": "4.1%"
                    },
                    "measures": "[Patients experiencing events]",
                    "outcomes": "[9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Hepatobiliary disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing events": "9",
                        "Percentage of patients experiencing events": "4.1%"
                    },
                    "measures": "[Patients experiencing events]",
                    "outcomes": "[9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Hepatobiliary disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing events": "9",
                        "Percentage of patients experiencing events": "4.1%"
                    },
                    "measures": "[Patients experiencing events]",
                    "outcomes": "[9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Hepatobiliary disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing events": "9",
                        "Percentage of patients experiencing events": "4.1%"
                    },
                    "measures": "[Patients experiencing events]",
                    "outcomes": "[9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Hepatobiliary disorders",
                        "HIV status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Event severity": "Grade 3 or 4",
                        "Patients experiencing events": "9",
                        "Percentage of patients experiencing events": "4.1%"
                    },
                    "measures": "[Patients experiencing events]",
                    "outcomes": "[9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 18,
        "total_ground_truth_claims": 10,
        "number_of_matches": 2
    },
    "PMC6937831_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "death_category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Cancer",
                        "number_of_deaths": "6",
                        "percentage": "4%",
                        "definition": "Based on the CoDe protocol, AIDS-related cancers like cervical cancer were considered as ARM and other causes unrelated to HIV like lung cancer were categorized as NARD"
                    },
                    "measures": "[number_of_deaths, percentage]",
                    "outcomes": "[6, 4%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Cancer",
                        "Protocol": "CoDe",
                        "ARM classification": "AIDS-related cancers",
                        "NARD classification": "Non-AIDS-related cancers"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "6",
                        "4%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "death_category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Other diseases",
                        "number_of_deaths": "10",
                        "percentage": "8%",
                        "definition": "Unknown death categorized based on CD4 count within 6-months prior to the date of death. The CD4 cell count of lower than 200 cells/mm\u00b2 was categorized as ARM and otherwise as NARM"
                    },
                    "measures": "[number_of_deaths, percentage]",
                    "outcomes": "[10, 8%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Other diseases",
                        "ARM classification": "CD4 ceel count lowen than 200 cells/mm2",
                        "NARD classification": "CD4 ceel count higher than 200 cells/mm2"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "10",
                        "8%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "death_category": "Non-AIDS-Related Death (NARD)",
                        "cause": "CVD",
                        "number_of_deaths": "12",
                        "percentage": "9%"
                    },
                    "measures": "[number_of_deaths, percentage]",
                    "outcomes": "[12, 9%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "CVD"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "12",
                        "9%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "death_category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Hepatic/liver-related",
                        "number_of_deaths": "34",
                        "percentage": "24%"
                    },
                    "measures": "[number_of_deaths, percentage]",
                    "outcomes": "[34, 24%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Hepatic/liver-related"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "34",
                        "24%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "death_category": "Non-AIDS-Related Death (NARD)",
                        "cause": "External death",
                        "number_of_deaths": "78",
                        "percentage": "55%",
                        "definition": "Sudden death, including accident, overdose, and suicide"
                    },
                    "measures": "[number_of_deaths, percentage]",
                    "outcomes": "[78, 55%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "External death",
                        "Cause of death": "sudden death, including accident, overdose and suicide"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "78",
                        "55%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "death_category": "AIDS-Related Death (ARD)",
                        "cause": "Other diseases",
                        "number_of_deaths": "2",
                        "percentage": "1%",
                        "definition": "Unknown death categorized based on CD4 count within 6-months prior to the date of death. The CD4 cell count of lower than 200 cells/mm\u00b2 was categorized as ARM and otherwise as NARM"
                    },
                    "measures": "[number_of_deaths, percentage]",
                    "outcomes": "[2, 1%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "AIDS-Related Death (ARD)",
                        "cause": "Other diseases",
                        "ARM classification": "CD4 ceel count lowen than 200 cells/mm2",
                        "NARD classification": "CD4 ceel count higher than 200 cells/mm2"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "2",
                        "1%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "death_category": "AIDS-Related Death (ARD)",
                        "cause": "Cancer",
                        "number_of_deaths": "8",
                        "percentage": "3%",
                        "definition": "Based on the CoDe protocol, AIDS-related cancers like cervical cancer were considered as ARM and other causes unrelated to HIV like lung cancer were categorized as NARD"
                    },
                    "measures": "[number_of_deaths, percentage]",
                    "outcomes": "[8, 3%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "AIDS-Related Death (ARD)",
                        "cause": "Cancer",
                        "Protocol": "CoDe",
                        "ARM classification": "AIDS-related cancers",
                        "NARD classification": "Non-AIDS-related cancers"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "8",
                        "3%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "death_category": "AIDS-Related Death (ARD)",
                        "cause": "Opportunistic",
                        "number_of_deaths": "241",
                        "percentage": "96%"
                    },
                    "measures": "[number_of_deaths, percentage]",
                    "outcomes": "[241, 96%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "AIDS-Related Death (ARD)",
                        "cause": "Opportunistic"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "241",
                        "96%"
                    ]
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 9,
        "total_ground_truth_claims": 8,
        "number_of_matches": 8
    },
    "PMC8340029_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "Including study visits with on-site PrEP access",
                        "time period": "Before access",
                        "number of infections/person-years": "133/2860",
                        "incidence": "4\u00b765%",
                        "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "Before access",
                        "data representation": "incidence",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "133",
                        "person-years": "2860",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[4.65%]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "Including study visits with on-site PrEP access",
                        "time period": "After access",
                        "number of infections/person-years": "12/556",
                        "incidence": "2\u00b716%",
                        "adjusted incidence rate ratio (95% CI)": "0\u00b745 (0\u00b725-0\u00b782)",
                        "p value": "0\u00b70085",
                        "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[adjusted incidence rate ratio (95% CI), p value]",
                    "outcomes": "[0\u00b745 (0\u00b725-0\u00b781), 0\u00b70076]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "Number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[2.16%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "Including study visits with on-site PrEP access",
                        "time period": "After access",
                        "number of infections/person-years": "12/556",
                        "incidence": "2\u00b716%",
                        "adjusted incidence rate ratio (95% CI)": "0\u00b745 (0\u00b725-0\u00b782)",
                        "p value": "0\u00b70085",
                        "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[adjusted incidence rate ratio (95% CI), p value]",
                    "outcomes": "[0\u00b745 (0\u00b725-0\u00b781), 0\u00b70076]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, 95% CI, p value]",
                    "outcomes": "[0.45, 0.25-0.81, 0.0076]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "Including study visits with on-site PrEP access",
                        "time period": "After access",
                        "number of infections/person-years": "12/556",
                        "incidence": "2\u00b716%",
                        "adjusted incidence rate ratio (95% CI)": "0\u00b745 (0\u00b725-0\u00b782)",
                        "p value": "0\u00b70085",
                        "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[adjusted incidence rate ratio (95% CI), p value]",
                    "outcomes": "[0\u00b745 (0\u00b725-0\u00b781), 0\u00b70076]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.45, (0.25-0.82), 0.0085]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "Including study visits with on-site PrEP access",
                        "time period": "After access",
                        "number of infections/person-years": "12/556",
                        "incidence": "2\u00b716%",
                        "adjusted incidence rate ratio (95% CI)": "0\u00b745 (0\u00b725-0\u00b782)",
                        "p value": "0\u00b70085",
                        "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[adjusted incidence rate ratio (95% CI), p value]",
                    "outcomes": "[0\u00b745 (0\u00b725-0\u00b781), 0\u00b70076]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "Before access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "46",
                        "person-years": "919",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[5.00%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "Including study visits with on-site PrEP access",
                        "time period": "After access",
                        "number of infections/person-years": "12/556",
                        "incidence": "2\u00b716%",
                        "adjusted incidence rate ratio (95% CI)": "0\u00b745 (0\u00b725-0\u00b782)",
                        "p value": "0\u00b70085",
                        "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[adjusted incidence rate ratio (95% CI), p value]",
                    "outcomes": "[0\u00b745 (0\u00b725-0\u00b781), 0\u00b70076]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[2.29%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "Including study visits with on-site PrEP access",
                        "time period": "After access",
                        "number of infections/person-years": "12/556",
                        "incidence": "2\u00b716%",
                        "adjusted incidence rate ratio (95% CI)": "0\u00b745 (0\u00b725-0\u00b782)",
                        "p value": "0\u00b70085",
                        "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[adjusted incidence rate ratio (95% CI), p value]",
                    "outcomes": "[0\u00b745 (0\u00b725-0\u00b781), 0\u00b70076]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.44, (0.23-0.85), 0.015]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "Including study visits with on-site PrEP access",
                        "time period": "After access",
                        "number of infections/person-years": "12/556",
                        "incidence": "2\u00b716%",
                        "adjusted incidence rate ratio (95% CI)": "0\u00b745 (0\u00b725-0\u00b782)",
                        "p value": "0\u00b70085",
                        "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[adjusted incidence rate ratio (95% CI), p value]",
                    "outcomes": "[0\u00b745 (0\u00b725-0\u00b781), 0\u00b70076]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.43, (0.22-0.83), 0.012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "time period": "Before access",
                        "number of infections/person-years": "46/919",
                        "incidence": "5\u00b700%",
                        "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "Number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[2.16%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "time period": "Before access",
                        "number of infections/person-years": "46/919",
                        "incidence": "5\u00b700%",
                        "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, 95% CI, p value]",
                    "outcomes": "[0.45, 0.25-0.81, 0.0076]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "time period": "Before access",
                        "number of infections/person-years": "46/919",
                        "incidence": "5\u00b700%",
                        "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.45, (0.25-0.82), 0.0085]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "time period": "Before access",
                        "number of infections/person-years": "46/919",
                        "incidence": "5\u00b700%",
                        "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "Before access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "46",
                        "person-years": "919",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[5.00%]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "time period": "After access",
                        "number of infections/person-years": "11/481",
                        "incidence": "2\u00b729%",
                        "adjusted incidence rate ratio (95% CI)": "0\u00b743 (0\u00b722-0\u00b783)",
                        "p value": "0\u00b7012",
                        "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[adjusted incidence rate ratio (95% CI), p value]",
                    "outcomes": "[0\u00b744 (0\u00b723-0\u00b785), 0\u00b7015]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "Number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[2.16%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "time period": "After access",
                        "number of infections/person-years": "11/481",
                        "incidence": "2\u00b729%",
                        "adjusted incidence rate ratio (95% CI)": "0\u00b743 (0\u00b722-0\u00b783)",
                        "p value": "0\u00b7012",
                        "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[adjusted incidence rate ratio (95% CI), p value]",
                    "outcomes": "[0\u00b744 (0\u00b723-0\u00b785), 0\u00b7015]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, 95% CI, p value]",
                    "outcomes": "[0.45, 0.25-0.81, 0.0076]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "time period": "After access",
                        "number of infections/person-years": "11/481",
                        "incidence": "2\u00b729%",
                        "adjusted incidence rate ratio (95% CI)": "0\u00b743 (0\u00b722-0\u00b783)",
                        "p value": "0\u00b7012",
                        "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[adjusted incidence rate ratio (95% CI), p value]",
                    "outcomes": "[0\u00b744 (0\u00b723-0\u00b785), 0\u00b7015]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.45, (0.25-0.82), 0.0085]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "time period": "After access",
                        "number of infections/person-years": "11/481",
                        "incidence": "2\u00b729%",
                        "adjusted incidence rate ratio (95% CI)": "0\u00b743 (0\u00b722-0\u00b783)",
                        "p value": "0\u00b7012",
                        "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[adjusted incidence rate ratio (95% CI), p value]",
                    "outcomes": "[0\u00b744 (0\u00b723-0\u00b785), 0\u00b7015]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[2.29%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "time period": "After access",
                        "number of infections/person-years": "11/481",
                        "incidence": "2\u00b729%",
                        "adjusted incidence rate ratio (95% CI)": "0\u00b743 (0\u00b722-0\u00b783)",
                        "p value": "0\u00b7012",
                        "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[adjusted incidence rate ratio (95% CI), p value]",
                    "outcomes": "[0\u00b744 (0\u00b723-0\u00b785), 0\u00b7015]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.44, (0.23-0.85), 0.015]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "time period": "After access",
                        "number of infections/person-years": "11/481",
                        "incidence": "2\u00b729%",
                        "adjusted incidence rate ratio (95% CI)": "0\u00b743 (0\u00b722-0\u00b783)",
                        "p value": "0\u00b7012",
                        "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[adjusted incidence rate ratio (95% CI), p value]",
                    "outcomes": "[0\u00b744 (0\u00b723-0\u00b785), 0\u00b7015]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.43, (0.22-0.83), 0.012]"
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 4,
        "total_ground_truth_claims": 8,
        "number_of_matches": 2
    },
    "PMC8391097_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "PrEP status": "Overall",
                        "HIV infections": "No./total No. of individuals, 91/13 861",
                        "Total follow-up": "person-years, 26 210",
                        "Incidence (95% CI)": "per 100 person-years, 0.35 (0.28-0.43)",
                        "Exclusion criteria": "Excludes individuals who were diagnosed with HIV during the eligibility assessment at PrEP linkage"
                    },
                    "measures": "[Incidence rate]",
                    "outcomes": "[0.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "HIV Incidence Rate Estimates",
                        "group": "Overall",
                        "HIV infections number": "91",
                        "Number of individuals": "13 861",
                        "total follow-up (person-years)": "26 210",
                        "incidence": "per 100 person-years",
                        "exclusion criteria": "Excludes individuals who were diagnosed with HIV during the eligibility assessment at PrEP linkage"
                    },
                    "measures": "[incidence rate, 95% CI]",
                    "outcomes": "[0.35 (0.28-0.43)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "PrEP status": "Linked but not prescribed PrEP",
                        "HIV infections": "No./total No. of individuals, 36/3013",
                        "Total follow-up": "person-years, 4119",
                        "Incidence (95% CI)": "per 100 person-years, 0.87 (0.63-1.21)"
                    },
                    "measures": "[Incidence rate]",
                    "outcomes": "[0.87]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "HIV Incidence Rate Estimates",
                        "group": "Linked but not prescribed PrEP",
                        "HIV infection number": "36",
                        "Total number of individuals": "3013",
                        "total follow-up (person-years)": "4119",
                        "incidence": "per 100 person-years"
                    },
                    "measures": "[incidence rate, 95% CI]",
                    "outcomes": "[0.87, (0.63-1.21)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "PrEP status": "Prescribed PrEP but did not initiate",
                        "HIV infections": "No./total No. of individuals, 13/811",
                        "Total follow-up": "person-years, 1226",
                        "Incidence (95% CI)": "per 100 person-years, 1.06 (0.62-1.83)"
                    },
                    "measures": "[Incidence rate]",
                    "outcomes": "[1.06]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "HIV Incidence Rate Estimates",
                        "group": "Prescribed PrEP but did not initiate",
                        "HIV infection number": "11",
                        "Total number of individuals": "811",
                        "total follow-up (person-years)": "1226",
                        "incidence": "per 100 person-years"
                    },
                    "measures": "[incidence rate, 95% CI]",
                    "outcomes": "[1.06, (0.62-1.83)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "PrEP status": "Discontinued but reinitiated PrEP",
                        "HIV infections": "No./total No. of individuals, 4/1082",
                        "Total follow-up": "person-years, 1420",
                        "Incidence (95% CI)": "per 100 person-years, 0.28 (0.11-0.75)"
                    },
                    "measures": "[Incidence rate]",
                    "outcomes": "[0.28]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "HIV Incidence Rate Estimates",
                        "group": "Discontinued but reinitiated PrEP",
                        "HIV infection number": "4",
                        "Total number of individuals": "1082",
                        "total follow-up (person-years)": "1420",
                        "incidence": "per 100 person-years"
                    },
                    "measures": "[incidence rate, 95% CI]",
                    "outcomes": "[0.28, (0.11-0.75)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "PrEP status": "Discontinued and did not reinitiate PrEP",
                        "HIV infections": "No./total No. of individuals, 38/2108",
                        "Total follow-up": "person-years, 2973",
                        "Incidence (95% CI)": "per 100 person-years, 1.28 (0.93-1.76)"
                    },
                    "measures": "[Incidence rate]",
                    "outcomes": "[1.28]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "HIV Incidence Rate Estimates",
                        "group": "Discontinued and did not reinitiate PrEP",
                        "HIV infection number": "38",
                        "Total number of individuals": "2108",
                        "total follow-up (person-years)": "2973",
                        "incidence": "per 100 person-years"
                    },
                    "measures": "[incidence rate, 95% CI]",
                    "outcomes": "[1.28, (0.93-1.76)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "PrEP status": "Persistent on PrEP",
                        "HIV infections": "No./total No. of individuals, 0/5367",
                        "Total follow-up": "person-years, 9139",
                        "Incidence (95% CI)": "per 100 person-years, 0.00 (0.00-0.04)",
                        "Definition": "Persistent on PrEP refers to individuals who initiated and remained on PrEP throughout follow-up",
                        "CI type": "One-sided 97.5% upper CI"
                    },
                    "measures": "[Incidence rate]",
                    "outcomes": "[0.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "HIV Incidence Rate Estimates",
                        "group": "Persistent on PrEP",
                        "HIV infection number": "0",
                        "Total number of individuals": "5367",
                        "total follow-up(person-years)": "9139",
                        "incidence": "per 100 person-years",
                        "definition": "Persistent on PrEP refers to individuals who initiated and remained on PrEP throughout follow-up",
                        "confidence interval": "One-sided 97.5% upper CI"
                    },
                    "measures": "[incidence rate, 97.5% CI]",
                    "outcomes": "[0.00, (0.00-0.04)]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 6,
        "total_ground_truth_claims": 6,
        "number_of_matches": 6
    },
    "PMC8748440_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "ISG15",
                        "HR": "0.29 (0.11\u20130.81)",
                        "p value": "0.0091",
                        "analysis type": "Univariable Cox regression",
                        "module": "salmon Module 1",
                        "identified by": "WGCNA"
                    },
                    "measures": "[HR, p value]",
                    "outcomes": "[0.29 (0.11\u20130.81), 0.0091]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "ISG15",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.29, 0.11\u20130.81 0.0091]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "IFI6",
                        "HR": "0.18 (0.037\u20130.86)",
                        "p value": "0.014",
                        "analysis type": "Univariable Cox regression",
                        "module": "salmon Module 1",
                        "identified by": "WGCNA"
                    },
                    "measures": "[HR, p value]",
                    "outcomes": "[0.18 (0.037\u20130.86), 0.014]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "IFI6",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.18, 0.037\u20130.86, 0.014]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "IFI44L",
                        "HR": "0.55 (0.27\u20131.1)",
                        "p value": "0.083",
                        "analysis type": "Univariable Cox regression",
                        "module": "salmon Module 1",
                        "identified by": "WGCNA"
                    },
                    "measures": "[HR, p value]",
                    "outcomes": "[0.55 (0.27\u20131.1), 0.083]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "IFI44L",
                        "module": "salmon Module 1"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.55, 0.27\u20131.1, 0.083]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "IFI44",
                        "HR": "0.23 (0.047\u20131.2)",
                        "p value": "0.045",
                        "analysis type": "Univariable Cox regression",
                        "module": "salmon Module 1",
                        "identified by": "WGCNA"
                    },
                    "measures": "[HR, p value]",
                    "outcomes": "[0.23 (0.047\u20131.2), 0.045]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "IFI44",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.23, 0.047\u20131.2, 0.045]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "IFIT1",
                        "HR": "0.37 (0.12\u20131.1)",
                        "p value": "0.054",
                        "analysis type": "Univariable Cox regression",
                        "module": "salmon Module 1",
                        "identified by": "WGCNA"
                    },
                    "measures": "[HR, p value]",
                    "outcomes": "[0.37 (0.12\u20131.1), 0.054]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "IFIT1",
                        "module": "salmon Module 1"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.37, 0.12\u20131.1, 0.054]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "OAS3",
                        "HR": "0.52 (0.22\u20131.3)",
                        "p value": "0.15",
                        "analysis type": "Univariable Cox regression",
                        "module": "salmon Module 1",
                        "identified by": "WGCNA"
                    },
                    "measures": "[HR, p value]",
                    "outcomes": "[0.52 (0.22\u20131.3), 0.15]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "OAS3",
                        "module": "salmon Module 1"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.52, 0.22\u20131.3, 0.15]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "XAF1",
                        "HR": "0.3 (0.1\u20130.92)",
                        "p value": "0.027",
                        "analysis type": "Univariable Cox regression",
                        "module": "salmon Module 1",
                        "identified by": "WGCNA"
                    },
                    "measures": "[HR, p value]",
                    "outcomes": "[0.3 (0.1\u20130.92), 0.027]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "XAF1",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.3, 0.1\u20130.92, 0.027]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "TRIM25",
                        "HR": "0.074 (0.0068\u20130.8)",
                        "p value": "0.023",
                        "analysis type": "Univariable Cox regression",
                        "module": "salmon Module 1",
                        "identified by": "WGCNA"
                    },
                    "measures": "[HR, p value]",
                    "outcomes": "[0.074 (0.0068\u20130.8), 0.023]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "TRIM25",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.074, 0.0068\u20130.8, 0.023]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "CMPK2",
                        "HR": "0.23 (0.037\u20131.5)",
                        "p value": "0.074",
                        "analysis type": "Univariable Cox regression",
                        "module": "salmon Module 1",
                        "identified by": "WGCNA"
                    },
                    "measures": "[HR, p value]",
                    "outcomes": "[0.23 (0.037\u20131.5), 0.074]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "CMPK2",
                        "module": "salmon Module 1"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.23, 0.037\u20131.5, 0.074]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "RSAD2",
                        "HR": "0.2 (0.041\u20130.99)",
                        "p value": "0.032",
                        "analysis type": "Univariable Cox regression",
                        "module": "salmon Module 1",
                        "identified by": "WGCNA"
                    },
                    "measures": "[HR, p value]",
                    "outcomes": "[0.2 (0.041\u20130.99), 0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "RSAD2",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.2, 0.041\u20130.99, 0.032]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "EIF2AK2",
                        "HR": "0.54 (0.12\u20132.4)",
                        "p value": "0.42",
                        "analysis type": "Univariable Cox regression",
                        "module": "salmon Module 1",
                        "identified by": "WGCNA"
                    },
                    "measures": "[HR, p value]",
                    "outcomes": "[0.54 (0.12\u20132.4), 0.42]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "EIF2AK2",
                        "module": "salmon Module 1"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.54, 0.12\u20132.4, 0.42]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "USP18",
                        "HR": "0.23 (0.062\u20130.84)",
                        "p value": "0.022",
                        "analysis type": "Univariable Cox regression",
                        "module": "salmon Module 1",
                        "identified by": "WGCNA"
                    },
                    "measures": "[HR, p value]",
                    "outcomes": "[0.23 (0.062\u20130.84), 0.022]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "USP18",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.23, 0.062\u20130.84, 0.022]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "HERC6",
                        "HR": "0.16 (0.019\u20131.3)",
                        "p value": "0.057",
                        "analysis type": "Univariable Cox regression",
                        "module": "salmon Module 1",
                        "identified by": "WGCNA"
                    },
                    "measures": "[HR, p value]",
                    "outcomes": "[0.16 (0.019\u20131.3), 0.057]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "HERC6",
                        "module": "salmon Module 1"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.16, 0.019\u20131.3, 0.057]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 13,
        "total_ground_truth_claims": 13,
        "number_of_matches": 13
    },
    "PMC7615197_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "intention-to-treat",
                        "treatment": "dexamethasone",
                        "control": "placebo",
                        "deaths_dexamethasone": "116/263",
                        "deaths_placebo": "126/257",
                        "hazard_ratio": "0.85",
                        "confidence_interval": "(0.66, 1.10)",
                        "p_value": "0.22",
                        "test_for_proportional_hazards": "0.36",
                        "heterogeneity_p_value": "not reported",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "treatment only"
                    },
                    "measures": "[hazard_ratio, confidence_interval, p_value]",
                    "outcomes": "[0.85, (0.66, 1.10), 0.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Intention-to-treat population",
                        "Deaths (Dexamethasone)": "116/263",
                        "Deaths (Placebo)": "126/257",
                        "Method": "Cox proportional hazards model",
                        "Test for proportional hazards": "0.36"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value]",
                    "outcomes": "[0.85, 0.66-1.10, 0.22]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "modified MRC grade",
                        "subgroup": "Grade I",
                        "treatment": "dexamethasone",
                        "control": "placebo",
                        "deaths_dexamethasone": "22/99",
                        "deaths_placebo": "28/97",
                        "hazard_ratio": "0.72",
                        "confidence_interval": "(0.41, 1.25)",
                        "p_value": "0.24",
                        "test_for_proportional_hazards": "0.15",
                        "heterogeneity_p_value": "0.63",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[hazard_ratio, confidence_interval, p_value]",
                    "outcomes": "[0.72, (0.41, 1.25), 0.24]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "I",
                        "Deaths (Dexamethasone)": "22/99",
                        "Deaths (Placebo)": "28/97",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.41-1.25, 0.24, 0.15, 0.63]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "modified MRC grade",
                        "subgroup": "Grade II",
                        "treatment": "dexamethasone",
                        "control": "placebo",
                        "deaths_dexamethasone": "60/125",
                        "deaths_placebo": "68/126",
                        "hazard_ratio": "0.82",
                        "confidence_interval": "(0.58, 1.16)",
                        "p_value": "0.27",
                        "test_for_proportional_hazards": "0.57",
                        "heterogeneity_p_value": "0.63",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[hazard_ratio, confidence_interval, p_value]",
                    "outcomes": "[0.82, (0.58, 1.16), 0.27]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "II",
                        "Deaths (Dexamethasone)": "60/125",
                        "Deaths (Placebo)": "68/126",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.82, 0.58-1.16, 0.27, 0.30, 0.63]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "modified MRC grade",
                        "subgroup": "Grade III",
                        "treatment": "dexamethasone",
                        "control": "placebo",
                        "deaths_dexamethasone": "34/39",
                        "deaths_placebo": "30/34",
                        "hazard_ratio": "1.11",
                        "confidence_interval": "(0.70, 1.77)",
                        "p_value": "0.65",
                        "test_for_proportional_hazards": "0.89",
                        "heterogeneity_p_value": "0.63",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[hazard_ratio, confidence_interval, p_value]",
                    "outcomes": "[1.11, (0.70, 1.77), 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "modified MRC grade",
                        "subgroup": "Grade III",
                        "treatment": "dexamethasone",
                        "control": "placebo",
                        "deaths_dexamethasone": "34/39",
                        "deaths_placebo": "30/34",
                        "hazard_ratio": "1.11",
                        "confidence_interval": "(0.70, 1.77)",
                        "p_value": "0.65",
                        "test_for_proportional_hazards": "0.89",
                        "heterogeneity_p_value": "0.63",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[hazard_ratio, confidence_interval, p_value]",
                    "outcomes": "[1.11, (0.70, 1.77), 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "modified MRC grade",
                        "subgroup": "Grade III",
                        "treatment": "dexamethasone",
                        "control": "placebo",
                        "deaths_dexamethasone": "34/39",
                        "deaths_placebo": "30/34",
                        "hazard_ratio": "1.11",
                        "confidence_interval": "(0.70, 1.77)",
                        "p_value": "0.65",
                        "test_for_proportional_hazards": "0.89",
                        "heterogeneity_p_value": "0.63",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[hazard_ratio, confidence_interval, p_value]",
                    "outcomes": "[1.11, (0.70, 1.77), 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "modified MRC grade",
                        "subgroup": "Grade III",
                        "treatment": "dexamethasone",
                        "control": "placebo",
                        "deaths_dexamethasone": "34/39",
                        "deaths_placebo": "30/34",
                        "hazard_ratio": "1.11",
                        "confidence_interval": "(0.70, 1.77)",
                        "p_value": "0.65",
                        "test_for_proportional_hazards": "0.89",
                        "heterogeneity_p_value": "0.63",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[hazard_ratio, confidence_interval, p_value]",
                    "outcomes": "[1.11, (0.70, 1.77), 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "modified MRC grade",
                        "subgroup": "Grade III",
                        "treatment": "dexamethasone",
                        "control": "placebo",
                        "deaths_dexamethasone": "34/39",
                        "deaths_placebo": "30/34",
                        "hazard_ratio": "1.11",
                        "confidence_interval": "(0.70, 1.77)",
                        "p_value": "0.65",
                        "test_for_proportional_hazards": "0.89",
                        "heterogeneity_p_value": "0.63",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[hazard_ratio, confidence_interval, p_value]",
                    "outcomes": "[1.11, (0.70, 1.77), 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "modified MRC grade",
                        "subgroup": "Grade III",
                        "treatment": "dexamethasone",
                        "control": "placebo",
                        "deaths_dexamethasone": "34/39",
                        "deaths_placebo": "30/34",
                        "hazard_ratio": "1.11",
                        "confidence_interval": "(0.70, 1.77)",
                        "p_value": "0.65",
                        "test_for_proportional_hazards": "0.89",
                        "heterogeneity_p_value": "0.63",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[hazard_ratio, confidence_interval, p_value]",
                    "outcomes": "[1.11, (0.70, 1.77), 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "modified MRC grade",
                        "subgroup": "Grade III",
                        "treatment": "dexamethasone",
                        "control": "placebo",
                        "deaths_dexamethasone": "34/39",
                        "deaths_placebo": "30/34",
                        "hazard_ratio": "1.11",
                        "confidence_interval": "(0.70, 1.77)",
                        "p_value": "0.65",
                        "test_for_proportional_hazards": "0.89",
                        "heterogeneity_p_value": "0.63",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[hazard_ratio, confidence_interval, p_value]",
                    "outcomes": "[1.11, (0.70, 1.77), 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "modified MRC grade",
                        "subgroup": "Grade III",
                        "treatment": "dexamethasone",
                        "control": "placebo",
                        "deaths_dexamethasone": "34/39",
                        "deaths_placebo": "30/34",
                        "hazard_ratio": "1.11",
                        "confidence_interval": "(0.70, 1.77)",
                        "p_value": "0.65",
                        "test_for_proportional_hazards": "0.89",
                        "heterogeneity_p_value": "0.63",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[hazard_ratio, confidence_interval, p_value]",
                    "outcomes": "[1.11, (0.70, 1.77), 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "modified MRC grade",
                        "subgroup": "Grade III",
                        "treatment": "dexamethasone",
                        "control": "placebo",
                        "deaths_dexamethasone": "34/39",
                        "deaths_placebo": "30/34",
                        "hazard_ratio": "1.11",
                        "confidence_interval": "(0.70, 1.77)",
                        "p_value": "0.65",
                        "test_for_proportional_hazards": "0.89",
                        "heterogeneity_p_value": "0.63",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[hazard_ratio, confidence_interval, p_value]",
                    "outcomes": "[1.11, (0.70, 1.77), 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "modified MRC grade",
                        "subgroup": "Grade III",
                        "treatment": "dexamethasone",
                        "control": "placebo",
                        "deaths_dexamethasone": "34/39",
                        "deaths_placebo": "30/34",
                        "hazard_ratio": "1.11",
                        "confidence_interval": "(0.70, 1.77)",
                        "p_value": "0.65",
                        "test_for_proportional_hazards": "0.89",
                        "heterogeneity_p_value": "0.63",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[hazard_ratio, confidence_interval, p_value]",
                    "outcomes": "[1.11, (0.70, 1.77), 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "modified MRC grade",
                        "subgroup": "Grade III",
                        "treatment": "dexamethasone",
                        "control": "placebo",
                        "deaths_dexamethasone": "34/39",
                        "deaths_placebo": "30/34",
                        "hazard_ratio": "1.11",
                        "confidence_interval": "(0.70, 1.77)",
                        "p_value": "0.65",
                        "test_for_proportional_hazards": "0.89",
                        "heterogeneity_p_value": "0.63",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[hazard_ratio, confidence_interval, p_value]",
                    "outcomes": "[1.11, (0.70, 1.77), 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "modified MRC grade",
                        "subgroup": "Grade III",
                        "treatment": "dexamethasone",
                        "control": "placebo",
                        "deaths_dexamethasone": "34/39",
                        "deaths_placebo": "30/34",
                        "hazard_ratio": "1.11",
                        "confidence_interval": "(0.70, 1.77)",
                        "p_value": "0.65",
                        "test_for_proportional_hazards": "0.89",
                        "heterogeneity_p_value": "0.63",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[hazard_ratio, confidence_interval, p_value]",
                    "outcomes": "[1.11, (0.70, 1.77), 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "modified MRC grade",
                        "subgroup": "Grade III",
                        "treatment": "dexamethasone",
                        "control": "placebo",
                        "deaths_dexamethasone": "34/39",
                        "deaths_placebo": "30/34",
                        "hazard_ratio": "1.11",
                        "confidence_interval": "(0.70, 1.77)",
                        "p_value": "0.65",
                        "test_for_proportional_hazards": "0.89",
                        "heterogeneity_p_value": "0.63",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[hazard_ratio, confidence_interval, p_value]",
                    "outcomes": "[1.11, (0.70, 1.77), 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "modified MRC grade",
                        "subgroup": "Grade III",
                        "treatment": "dexamethasone",
                        "control": "placebo",
                        "deaths_dexamethasone": "34/39",
                        "deaths_placebo": "30/34",
                        "hazard_ratio": "1.11",
                        "confidence_interval": "(0.70, 1.77)",
                        "p_value": "0.65",
                        "test_for_proportional_hazards": "0.89",
                        "heterogeneity_p_value": "0.63",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[hazard_ratio, confidence_interval, p_value]",
                    "outcomes": "[1.11, (0.70, 1.77), 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "modified MRC grade",
                        "subgroup": "Grade III",
                        "treatment": "dexamethasone",
                        "control": "placebo",
                        "deaths_dexamethasone": "34/39",
                        "deaths_placebo": "30/34",
                        "hazard_ratio": "1.11",
                        "confidence_interval": "(0.70, 1.77)",
                        "p_value": "0.65",
                        "test_for_proportional_hazards": "0.89",
                        "heterogeneity_p_value": "0.63",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[hazard_ratio, confidence_interval, p_value]",
                    "outcomes": "[1.11, (0.70, 1.77), 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "modified MRC grade",
                        "subgroup": "Grade III",
                        "treatment": "dexamethasone",
                        "control": "placebo",
                        "deaths_dexamethasone": "34/39",
                        "deaths_placebo": "30/34",
                        "hazard_ratio": "1.11",
                        "confidence_interval": "(0.70, 1.77)",
                        "p_value": "0.65",
                        "test_for_proportional_hazards": "0.89",
                        "heterogeneity_p_value": "0.63",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[hazard_ratio, confidence_interval, p_value]",
                    "outcomes": "[1.11, (0.70, 1.77), 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "modified MRC grade",
                        "subgroup": "Grade III",
                        "treatment": "dexamethasone",
                        "control": "placebo",
                        "deaths_dexamethasone": "34/39",
                        "deaths_placebo": "30/34",
                        "hazard_ratio": "1.11",
                        "confidence_interval": "(0.70, 1.77)",
                        "p_value": "0.65",
                        "test_for_proportional_hazards": "0.89",
                        "heterogeneity_p_value": "0.63",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[hazard_ratio, confidence_interval, p_value]",
                    "outcomes": "[1.11, (0.70, 1.77), 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "intention-to-treat",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "treatment only",
                        "heterogeneity_of_effect": "not observed",
                        "subgroup_analysis": "pre-specified sub-groups",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "heterogeneity_test_method": "likelihood ratio test",
                        "interaction_model": "treatment effect and subgroup",
                        "subgroup_covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "intention-to-treat",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "treatment only",
                        "heterogeneity_of_effect": "not observed",
                        "subgroup_analysis": "pre-specified sub-groups",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "heterogeneity_test_method": "likelihood ratio test",
                        "interaction_model": "treatment effect and subgroup",
                        "subgroup_covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "intention-to-treat",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "treatment only",
                        "heterogeneity_of_effect": "not observed",
                        "subgroup_analysis": "pre-specified sub-groups",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "heterogeneity_test_method": "likelihood ratio test",
                        "interaction_model": "treatment effect and subgroup",
                        "subgroup_covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "intention-to-treat",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "treatment only",
                        "heterogeneity_of_effect": "not observed",
                        "subgroup_analysis": "pre-specified sub-groups",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "heterogeneity_test_method": "likelihood ratio test",
                        "interaction_model": "treatment effect and subgroup",
                        "subgroup_covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "intention-to-treat",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "treatment only",
                        "heterogeneity_of_effect": "not observed",
                        "subgroup_analysis": "pre-specified sub-groups",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "heterogeneity_test_method": "likelihood ratio test",
                        "interaction_model": "treatment effect and subgroup",
                        "subgroup_covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "intention-to-treat",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "treatment only",
                        "heterogeneity_of_effect": "not observed",
                        "subgroup_analysis": "pre-specified sub-groups",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "heterogeneity_test_method": "likelihood ratio test",
                        "interaction_model": "treatment effect and subgroup",
                        "subgroup_covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "intention-to-treat",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "treatment only",
                        "heterogeneity_of_effect": "not observed",
                        "subgroup_analysis": "pre-specified sub-groups",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "heterogeneity_test_method": "likelihood ratio test",
                        "interaction_model": "treatment effect and subgroup",
                        "subgroup_covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "intention-to-treat",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "treatment only",
                        "heterogeneity_of_effect": "not observed",
                        "subgroup_analysis": "pre-specified sub-groups",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "heterogeneity_test_method": "likelihood ratio test",
                        "interaction_model": "treatment effect and subgroup",
                        "subgroup_covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "intention-to-treat",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "treatment only",
                        "heterogeneity_of_effect": "not observed",
                        "subgroup_analysis": "pre-specified sub-groups",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "heterogeneity_test_method": "likelihood ratio test",
                        "interaction_model": "treatment effect and subgroup",
                        "subgroup_covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "intention-to-treat",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "treatment only",
                        "heterogeneity_of_effect": "not observed",
                        "subgroup_analysis": "pre-specified sub-groups",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "heterogeneity_test_method": "likelihood ratio test",
                        "interaction_model": "treatment effect and subgroup",
                        "subgroup_covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "intention-to-treat",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "treatment only",
                        "heterogeneity_of_effect": "not observed",
                        "subgroup_analysis": "pre-specified sub-groups",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "heterogeneity_test_method": "likelihood ratio test",
                        "interaction_model": "treatment effect and subgroup",
                        "subgroup_covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "intention-to-treat",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "treatment only",
                        "heterogeneity_of_effect": "not observed",
                        "subgroup_analysis": "pre-specified sub-groups",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "heterogeneity_test_method": "likelihood ratio test",
                        "interaction_model": "treatment effect and subgroup",
                        "subgroup_covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "intention-to-treat",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "treatment only",
                        "heterogeneity_of_effect": "not observed",
                        "subgroup_analysis": "pre-specified sub-groups",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "heterogeneity_test_method": "likelihood ratio test",
                        "interaction_model": "treatment effect and subgroup",
                        "subgroup_covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "intention-to-treat",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "treatment only",
                        "heterogeneity_of_effect": "not observed",
                        "subgroup_analysis": "pre-specified sub-groups",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "heterogeneity_test_method": "likelihood ratio test",
                        "interaction_model": "treatment effect and subgroup",
                        "subgroup_covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "intention-to-treat",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "treatment only",
                        "heterogeneity_of_effect": "not observed",
                        "subgroup_analysis": "pre-specified sub-groups",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "heterogeneity_test_method": "likelihood ratio test",
                        "interaction_model": "treatment effect and subgroup",
                        "subgroup_covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "intention-to-treat",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "treatment only",
                        "heterogeneity_of_effect": "not observed",
                        "subgroup_analysis": "pre-specified sub-groups",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "heterogeneity_test_method": "likelihood ratio test",
                        "interaction_model": "treatment effect and subgroup",
                        "subgroup_covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "population": "intention-to-treat",
                        "analysis_method": "Cox proportional hazards regression model",
                        "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                        "time_transformation": "Kaplan-Meier",
                        "covariates": "treatment only",
                        "heterogeneity_of_effect": "not observed",
                        "subgroup_analysis": "pre-specified sub-groups",
                        "primary_endpoint": "death from any cause over the first 12 months after randomization",
                        "heterogeneity_test_method": "likelihood ratio test",
                        "interaction_model": "treatment effect and subgroup",
                        "subgroup_covariates": "TBM MRC severity grade at enrolment"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 5,
        "total_ground_truth_claims": 20,
        "number_of_matches": 3
    },
    "PMC9008168_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population": "participants at risk",
                        "total_population": "2144",
                        "developed_BMI_\u226525_kg/m\u00b2": "516",
                        "table_reference": "Table 2",
                        "incidence_rate_comparison": "similar among participants without HIV and those on ART",
                        "highest_incidence_group": "participants on non-TLD ART"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population": "participants at risk",
                        "total_population": "2144",
                        "developed_BMI_\u226525_kg/m\u00b2": "516",
                        "table_reference": "Table 2",
                        "incidence_rate_comparison": "similar among participants without HIV and those on ART",
                        "highest_incidence_group": "participants on non-TLD ART"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population": "participants at risk",
                        "total_population": "2144",
                        "developed_BMI_\u226525_kg/m\u00b2": "516",
                        "table_reference": "Table 2",
                        "incidence_rate_comparison": "similar among participants without HIV and those on ART",
                        "highest_incidence_group": "participants on non-TLD ART"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study_population": "participants at risk",
                        "total_population": "2144",
                        "developed_BMI_\u226525_kg/m\u00b2": "516",
                        "table_reference": "Table 2",
                        "incidence_rate_comparison": "similar among participants without HIV and those on ART",
                        "highest_incidence_group": "participants on non-TLD ART"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "People without HIV",
                        "Person-time": "937.23",
                        "Failures": "65",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[69.80, (54.74\u201389.01)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "group": "Participants without HIV",
                        "incidence_rate_cases_per_1000_PY": "69.8",
                        "incidence_rate_95%_CI": "54.7\u201389.0",
                        "HR": "1.00",
                        "HR_reference": "Reference"
                    },
                    "measures": "[incidence_rate_cases_per_1000_PY, HR]",
                    "outcomes": "[69.8, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "group": "Participants without HIV",
                        "incidence_rate_cases_per_1000_PY": "69.8",
                        "incidence_rate_95%_CI": "54.7\u201389.0",
                        "HR": "1.00",
                        "HR_reference": "Reference"
                    },
                    "measures": "[incidence_rate_cases_per_1000_PY, HR]",
                    "outcomes": "[69.8, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "group": "Participants without HIV",
                        "incidence_rate_cases_per_1000_PY": "69.8",
                        "incidence_rate_95%_CI": "54.7\u201389.0",
                        "HR": "1.00",
                        "HR_reference": "Reference"
                    },
                    "measures": "[incidence_rate_cases_per_1000_PY, HR]",
                    "outcomes": "[69.8, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "group": "Participants without HIV",
                        "incidence_rate_cases_per_1000_PY": "69.8",
                        "incidence_rate_95%_CI": "54.7\u201389.0",
                        "HR": "1.00",
                        "HR_reference": "Reference"
                    },
                    "measures": "[incidence_rate_cases_per_1000_PY, HR]",
                    "outcomes": "[69.8, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "People without HIV",
                        "Person-time": "937.23",
                        "Failures": "65",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[69.80, (54.74\u201389.01)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "group": "PLWH on non-TLD ART",
                        "incidence_rate_cases_per_1000_PY": "77.1",
                        "incidence_rate_95%_CI": "69.8\u201385.2",
                        "HR": "1.13",
                        "HR_95%_CI": "0.79\u20131.63"
                    },
                    "measures": "[incidence_rate_cases_per_1000_PY, HR]",
                    "outcomes": "[77.1, 1.13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "group": "PLWH on non-TLD ART",
                        "incidence_rate_cases_per_1000_PY": "77.1",
                        "incidence_rate_95%_CI": "69.8\u201385.2",
                        "HR": "1.13",
                        "HR_95%_CI": "0.79\u20131.63"
                    },
                    "measures": "[incidence_rate_cases_per_1000_PY, HR]",
                    "outcomes": "[77.1, 1.13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "group": "PLWH on non-TLD ART",
                        "incidence_rate_cases_per_1000_PY": "77.1",
                        "incidence_rate_95%_CI": "69.8\u201385.2",
                        "HR": "1.13",
                        "HR_95%_CI": "0.79\u20131.63"
                    },
                    "measures": "[incidence_rate_cases_per_1000_PY, HR]",
                    "outcomes": "[77.1, 1.13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "group": "PLWH on TLD",
                        "incidence_rate_cases_per_1000_PY": "73.3",
                        "incidence_rate_95%_CI": "54.0\u201399.6",
                        "HR": "1.77",
                        "HR_95%_CI": "1.22\u20132.55"
                    },
                    "measures": "[incidence_rate_cases_per_1000_PY, HR]",
                    "outcomes": "[73.3, 1.77]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "group": "PLWH on TLD",
                        "incidence_rate_cases_per_1000_PY": "73.3",
                        "incidence_rate_95%_CI": "54.0\u201399.6",
                        "HR": "1.77",
                        "HR_95%_CI": "1.22\u20132.55"
                    },
                    "measures": "[incidence_rate_cases_per_1000_PY, HR]",
                    "outcomes": "[73.3, 1.77]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "group": "PLWH on TLD",
                        "incidence_rate_cases_per_1000_PY": "73.3",
                        "incidence_rate_95%_CI": "54.0\u201399.6",
                        "HR": "1.77",
                        "HR_95%_CI": "1.22\u20132.55"
                    },
                    "measures": "[incidence_rate_cases_per_1000_PY, HR]",
                    "outcomes": "[73.3, 1.77]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "group": "PLWH, ART na\u00efve",
                        "incidence_rate_cases_per_1000_PY": "37.7",
                        "incidence_rate_95%_CI": "24.1\u201359.1",
                        "HR": "0.43",
                        "HR_95%_CI": "0.27\u20130.70"
                    },
                    "measures": "[incidence_rate_cases_per_1000_PY, HR]",
                    "outcomes": "[37.7, 0.43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "group": "PLWH, ART na\u00efve",
                        "incidence_rate_cases_per_1000_PY": "37.7",
                        "incidence_rate_95%_CI": "24.1\u201359.1",
                        "HR": "0.43",
                        "HR_95%_CI": "0.27\u20130.70"
                    },
                    "measures": "[incidence_rate_cases_per_1000_PY, HR]",
                    "outcomes": "[37.7, 0.43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "group": "PLWH, ART na\u00efve",
                        "incidence_rate_cases_per_1000_PY": "37.7",
                        "incidence_rate_95%_CI": "24.1\u201359.1",
                        "HR": "0.43",
                        "HR_95%_CI": "0.27\u20130.70"
                    },
                    "measures": "[incidence_rate_cases_per_1000_PY, HR]",
                    "outcomes": "[37.7, 0.43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "abbreviation_PLWH": "people living with HIV",
                        "abbreviation_TLD": "tenofovir/lamivudine/dolutegravir",
                        "abbreviation_PY": "person-years"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "abbreviation_PLWH": "people living with HIV",
                        "abbreviation_TLD": "tenofovir/lamivudine/dolutegravir",
                        "abbreviation_PY": "person-years"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "abbreviation_PLWH": "people living with HIV",
                        "abbreviation_TLD": "tenofovir/lamivudine/dolutegravir",
                        "abbreviation_PY": "person-years"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 6,
        "total_ground_truth_claims": 4,
        "number_of_matches": 1
    },
    "PMC7644038_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "condition": "Depression",
                        "population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "comparison group": "No HIV",
                        "comparison group prevalence": "6.2%",
                        "HIV group prevalence": "24.3%",
                        "percent difference": "291.9%",
                        "significance level": "***",
                        "logistic regression model": "Coefficients from logistic regression model",
                        "odds ratio": "2.29",
                        "confidence interval": "[2.22, 2.35]",
                        "year": "2016",
                        "upper age limit": "98 years",
                        "statistical test": "chi-squared test",
                        "controls": "age, race/ethnicity, sex, state, rural/urban residence, dual enrollment in Medicaid",
                        "omitted group": "White, urban, non-Medicaid enrolled males between the age of 65 and 74",
                        "weighting": "probability weights to reflect differential selection probabilities based on HIV diagnosis",
                        "Bonferroni correction": "applied",
                        "number of tests": "11"
                    },
                    "measures": "[2.22, 2.35]",
                    "outcomes": [
                        "[24.3%, 6.2%, 291.9%, 2.29]",
                        "[HIV group prevalence, comparison group prevalence, percent difference, odds ratio]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Depression",
                        "HIV Prevalence": "24.3%",
                        "No HIV Prevalence": "6.2%",
                        "Percent Difference": "291.9%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[2.29, 2.22-2.35]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "condition": "Chronic kidney disease",
                        "population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "comparison group": "No HIV",
                        "comparison group prevalence": "18.9%",
                        "HIV group prevalence": "46.2%",
                        "percent difference": "144.4%",
                        "significance level": "***",
                        "logistic regression model": "Coefficients from logistic regression model",
                        "odds ratio": "1.92",
                        "confidence interval": "[1.88, 1.97]",
                        "year": "2016",
                        "upper age limit": "98 years",
                        "statistical test": "chi-squared test",
                        "controls": "age, race/ethnicity, sex, state, rural/urban residence, dual enrollment in Medicaid",
                        "omitted group": "White, urban, non-Medicaid enrolled males between the age of 65 and 74",
                        "weighting": "probability weights to reflect differential selection probabilities based on HIV diagnosis",
                        "Bonferroni correction": "applied",
                        "number of tests": "11"
                    },
                    "measures": "[1.88, 1.97]",
                    "outcomes": [
                        "[46.2%, 18.9%, 144.4%, 1.92]",
                        "[HIV group prevalence, comparison group prevalence, percent difference, odds ratio]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Chronic kidney disease",
                        "HIV Prevalence": "46.2%",
                        "No HIV Prevalence": "18.9%",
                        "Percent Difference": "144.4%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.92, 1.88-1.97]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 2,
        "total_ground_truth_claims": 11,
        "number_of_matches": 2
    },
    "PMC6033411_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Age (years)",
                        "Age group": "15 and younger",
                        "Total number": "69 (34.5%)",
                        "Clustered": "22 (37.3%)",
                        "Odds ratio": "1.0 (ref)",
                        "P-value": "\u2026"
                    },
                    "measures": "[Odds ratio]",
                    "outcomes": "[1.0 (ref)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "15 and younger",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Age (years)",
                        "Age group": "16",
                        "Total number": "46 (23%)",
                        "Clustered": "13 (22%)",
                        "Odds ratio": "0.84 (0.36\u20131.89)",
                        "P-value": "0.67"
                    },
                    "measures": "[Odds ratio, P-value]",
                    "outcomes": "[0.84 (0.36\u20131.89), 0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "16",
                        "total participants": "46 (23%)",
                        "clustered participants": "13 (22%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.84 (0.36\u20131.89), 0.67]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Age (years)",
                        "Age group": "17+",
                        "Total number": "85 (42.5%)",
                        "Clustered": "24 (40.7%)",
                        "Odds ratio": "0.87 (0.43\u20131.76)",
                        "P-value": "0.69"
                    },
                    "measures": "[Odds ratio, P-value]",
                    "outcomes": "[0.87 (0.43\u20131.76), 0.69]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "17+",
                        "total participants": "85 (42.5%)",
                        "clustered participants": "24 (40.7%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.87 (0.43\u20131.76), 0.69]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "School grade",
                        "Grade group": "8\u20139",
                        "Total number": "90 (45%)",
                        "Clustered": "30 (50.8%)",
                        "Odds ratio": "1.0 (ref)",
                        "P-value": "\u2026"
                    },
                    "measures": "[Odds ratio]",
                    "outcomes": "[1.0 (ref)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "School grade",
                        "grade group": "8\u20139",
                        "total participants": "90 (45%)",
                        "clustered participants": "30 (50.8%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "School grade",
                        "Grade group": "10\u201312",
                        "Total number": "110 (55%)",
                        "Clustered": "29 (49.2%)",
                        "Odds ratio": "0.8 (0.43\u20131.52)",
                        "P-value": "0.5"
                    },
                    "measures": "[Odds ratio, P-value]",
                    "outcomes": "[0.8 (0.43\u20131.52), 0.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "School grade",
                        "grade group": "10\u201312",
                        "total participants": "110 (55%)",
                        "clustered participants": "29 (49.2%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.8 (0.43\u20131.52), 0.5]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Household income (R)",
                        "Income group": "<999",
                        "Total number": "61 (30.5%)",
                        "Clustered": "22 (37.3%)",
                        "Odds ratio": "1.0 (ref)",
                        "P-value": "\u2026"
                    },
                    "measures": "[Odds ratio]",
                    "outcomes": "[1.0 (ref)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Household income (R)",
                        "income group": "<999",
                        "total participants": "61 (30.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Household income (R)",
                        "Income group": "10,000\u201399,000",
                        "Total number": "112 (56%)",
                        "Clustered": "27 (45.8%)",
                        "Odds ratio": "0.56 (0.29\u20131.11)",
                        "P-value": "0.1"
                    },
                    "measures": "[Odds ratio, P-value]",
                    "outcomes": "[0.56 (0.29\u20131.11), 0.1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Household income (R)",
                        "income group": "10,000\u201399,000",
                        "total participants": "112 (56%)",
                        "clustered participants": "27 (45.8%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.56 (0.29\u20131.11), 0.1]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Household income (R)",
                        "Income group": ">100,000",
                        "Total number": "27 (12.5%)",
                        "Clustered": "10 (16.9%)",
                        "Odds ratio": "1.04 (0.39\u20132.65)",
                        "P-value": "0.93"
                    },
                    "measures": "[Odds ratio, P-value]",
                    "outcomes": "[1.04 (0.39\u20132.65), 0.93]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Household income (R)",
                        "income group": ">100,000",
                        "total participants": "27 (12.5%)",
                        "clustered participants": "10 (16.9%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.04 (0.39\u20132.65), 0.93]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": ">500",
                        "Total number": "92 (46%)",
                        "Clustered": "30 (50.9%)",
                        "Odds ratio": "1.0 (ref)",
                        "P-value": "\u2026"
                    },
                    "measures": "[Odds ratio]",
                    "outcomes": "[1.0 (ref)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": ">500",
                        "total participants": "92 (46%)",
                        "clustered participants": "30 (50.9%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": "\u2264500",
                        "Total number": "75 (37.5%)",
                        "Clustered": "19 (32.2%)",
                        "Odds ratio": "0.70 (0.35\u20131.37)",
                        "P-value": "0.31"
                    },
                    "measures": "[Odds ratio, P-value]",
                    "outcomes": "[0.70 (0.35\u20131.37), 0.31]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": "\u2264500",
                        "total participants": "75 (37.5%)",
                        "clustered participants": "19 (32.2%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.70 (0.35\u20131.37), 0.31]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": "\u2264250",
                        "Total number": "15 (7.5%)",
                        "Clustered": "4 (6.8%)",
                        "Odds ratio": "0.75 (0.2\u20132.4)",
                        "P-value": "0.65"
                    },
                    "measures": "[Odds ratio, P-value]",
                    "outcomes": "[0.75 (0.2\u20132.4), 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": "\u2264250",
                        "total participants": "15 (7.5%)",
                        "clustered participants": "4 (6.8%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.75 (0.2\u20132.4), 0.65]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Major drug resistance mutation",
                        "Mutation status": "No",
                        "Total number": "180 (90%)",
                        "Clustered": "55 (93.2)",
                        "Odds ratio": "1.0 (ref)",
                        "P-value": "\u2026"
                    },
                    "measures": "[Odds ratio]",
                    "outcomes": "[1.0 (ref)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Major drug resistance mutation",
                        "mutation status": "No",
                        "total participants": "180 (90%)",
                        "clustered participants": "55 (93.2)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Major drug resistance mutation",
                        "Mutation status": "Yes",
                        "Total number": "20 (10%)",
                        "Clustered": "4 (6.8%)",
                        "Odds ratio": "0.57 (0.16\u20131.63)",
                        "P-value": "0.33"
                    },
                    "measures": "[Odds ratio, P-value]",
                    "outcomes": "[0.57 (0.16\u20131.63), 0.33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Major drug resistance mutation",
                        "mutation status": "Yes",
                        "total participants": "20 (10%)",
                        "clustered participants": "4 (6.8%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.57 (0.16\u20131.63), 0.33]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "HSV-2 infection",
                        "HSV-2 status": "No",
                        "Total number": "90 (45%)",
                        "Clustered": "25 (42.4%)",
                        "Odds ratio": "1.0 (ref)",
                        "P-value": "\u2026"
                    },
                    "measures": "[Odds ratio]",
                    "outcomes": "[1.0 (ref)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "HSV-2 infection",
                        "infection status": "No",
                        "total participants": "90 (45%)",
                        "clustered participants": "25 (42.4%)",
                        "footnote": "HSV-2 infection status was not available for 41 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "HSV-2 infection",
                        "HSV-2 status": "Yes",
                        "Total number": "69 (34.5%)",
                        "Clustered": "23 (39%)",
                        "Odds ratio": "1.3 (0.65\u20132.57)",
                        "P-value": "0.45"
                    },
                    "measures": "[Odds ratio, P-value]",
                    "outcomes": "[1.3 (0.65\u20132.57), 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "HSV-2 infection",
                        "infection status": "Yes",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "23 (39%)",
                        "footnote": "HSV-2 infection status was not available for 41 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.3 (0.65\u20132.57), 0.45]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Ever pregnant",
                        "Pregnancy history": "No",
                        "Total number": "122 (61%)",
                        "Clustered": "37 (62.7%)",
                        "Odds ratio": "1.0 (ref)",
                        "P-value": "\u2026"
                    },
                    "measures": "[Odds ratio]",
                    "outcomes": "[1.0 (ref)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Ever pregnant",
                        "pregnancy status": "No",
                        "total participants": "122 (61%)",
                        "clustered participants": "37 (62.7%)",
                        "footnote": "Pregnancy history was not available for 29 women"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Ever pregnant",
                        "Pregnancy history": "Yes",
                        "Total number": "49 (24.5%)",
                        "Clustered": "15 (25.4%)",
                        "Odds ratio": "1.01 (0.48\u20132.06)",
                        "P-value": "0.971"
                    },
                    "measures": "[Odds ratio, P-value]",
                    "outcomes": "[1.01 (0.48\u20132.06), 0.971]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Ever pregnant",
                        "pregnancy status": "Yes",
                        "total participants": "49 (24.5%)",
                        "clustered participants": "15 (25.4%)",
                        "footnote": "Pregnancy history was not available for 29 women"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.01 (0.48\u20132.06), 0.971]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 18,
        "total_ground_truth_claims": 17,
        "number_of_matches": 17
    }
}